Compositions and methods for the treatment of epilepsy
SiRNA molecules selectively silence KCNT1 gene expression, addressing the limitations of current therapies by providing targeted KCNT1 reduction, thereby preventing epilepsy onset or progression.
Patent Information
- Application Number
- JP2024532709
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
AI Technical Summary
Current therapies for KCNT1-driven epilepsy lack selectivity and efficacy in targeting the sodium-activated potassium channel subfamily T member 1 (KCNT1), as they often affect related channels and are not effective against multiple KCNT1 alleles, posing challenges for small molecules.
The use of small interfering RNA (siRNA) molecules to silence KCNT1 gene expression by reducing KCNT1 mRNA translation, providing high selectivity for KCNT1 over other central nervous system genes, administered through various routes including intrathecal, intraventricular, and intracranial injections.
The siRNA molecules effectively reduce KCNT1 expression, preventing disease onset or progression in individuals with KCNT1 mutations, offering a targeted therapeutic approach with minimal impact on other channels.
Smart Images

Figure 2024542728000078 
Figure 2024542728000001 
Figure 2024542728000002
Abstract
Description
[Technical field]
[0001] The present disclosure relates to small interfering RNA (siRNA) molecules targeting the RNA transcript (e.g., mRNA) of the sodium-activated potassium channel subfamily T member 1 (KCNT1) gene and compositions containing the same. The present disclosure further describes a method for treating epilepsy syndromes by delivering KCNT1-targeting siRNA molecules to the central nervous system of a subject in need thereof. [Background technology]
[0002] Epilepsy is a heterogeneous disorder caused by abnormalities in neuronal excitability and synchronization of neuronal firing. There are many forms of epilepsy that are mechanistically and symptomatically different. Genetic epilepsy syndromes can be disabling or even fatal in childhood, and existing first-line anticonvulsant drugs such as zonisamide, phenytoin, mexiletine, lamotrigine, and carbamazepine are largely ineffective in the most severe syndromes.
[0003] One of the single genetic drivers of epilepsy is the sodium-activated potassium channel subfamily T member 1 (KCNT1) gene (SLACK, K Na 1.1, and Slo2.2), which is a voltage-dependent potassium ion (K + KCNT1 is one of over 80 homologous genes that encode members of the KCNT1 channel family. The complete potassium channel protein is a tetramer that can be monomeric or heteromeric. The channels formed by KCNT1 are opened by depolarizing voltages and intracellular calcium or sodium ions. KCNT1-driven epilepsy is poly-allelic in that many different individual mutations in KCNT1 can cause epilepsy, and no single variant causes most cases of the disease.
[0004] Challenges remain to generate therapeutic inhibitors that target the KCNT1 protein and reduce KCNT1 function. First, the pathological effects of KCNT1 variants may be mediated not only by monomeric KCNT1 channels but also by other K + It may also be exerted by channels incorporating polypeptide subunits encoded by channel genes, particularly other members of the KCa family. The targets at the protein level are not fully known, and inhibitors of monomeric KCNT1 channels may not inhibit all pathological KCNT1 functions. Second, more than 80 genes are known to encode K + It encodes the channel subunit, K + The channel drives important cardiac, metabolic, and neurological functions. For KCNT1-targeted therapies to be successful, KCNT1 must be regulated to circumvent cardiac and neurological disease liability. + It is desirable to show high selectivity for channel paralogs. Such selectivity has been difficult to achieve. Moreover, successful KCNT1-targeted therapies would require inhibition of channels formed by most or all of the many epilepsy-causing KCNT1 alleles, which can be a challenge for small molecules.
[0005] Therefore, it is expected that other K + There remains a need for therapeutic agents that can selectively reduce KCNT1 activity relative to channel-encoding genes. Summary of the Invention
[0006] The present disclosure provides compositions and methods for reducing expression of sodium-activated potassium channel subfamily T member 1 (KCNT1) by small interfering RNA (siRNA)-mediated silencing of the KCNT1 transcript. The compositions and methods are directed to reducing expression of other K + It offers the advantage of being highly selective for KCNT1 over other central nervous system (CNS) genes, including those encoding channels.
[0007] The siRNA molecule of the present disclosure can be used to silence KCNT1 gene, thereby preventing the translation of corresponding mRNA transcripts and reducing the expression of KCNT1.By reducing KCNT1 level in this way, the onset or progression of disease is prevented.The siRNA molecule of the present disclosure can be administered to pre-symptomatic individuals identified as having KCNT1 gain-of-function mutations.The siRNA molecule of the present disclosure can be delivered directly to the CNS of the subject who needs KCNT1 silencing, for example, by intrathecal, intracerebroventricular, intrastriatal, intraparenchymal, intracisternal injection by catheter insertion, intravenous injection, subcutaneous injection, or intramuscular injection.
[0008] In one aspect, the present disclosure provides an siRNA molecule comprising an antisense strand and a sense strand having complementarity with the antisense strand. The antisense strand has sufficient complementarity to hybridize to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224. In some embodiments, the antisense strand has sufficient complementarity to hybridize to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654. The antisense strand may be, for example, 10 to 50 nucleotides in length (e.g., 10 to 45 nucleotides in length, 10 to 40 nucleotides in length, 10 to 35 nucleotides in length, 10 to 30 nucleotides in length, 10 to 29 nucleotides in length, 10 to 28 nucleotides in length, 10 to 27 nucleotides in length, 10 to 26 nucleotides in length, 10 to 25 nucleotides in length, 10 to 24 nucleotides in length, 10 to 23 nucleotides in length, 10 to 22 nucleotides in length, 10 to 21 nucleotides in length, or 10 to 20 nucleotides in length). In some embodiments, the antisense strand is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides in length.
[0009] In some embodiments of any of the aforementioned aspects, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 15 consecutive nucleic acid bases in a KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 16 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 17 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 18 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 19 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 20 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 21 consecutive nucleic acid bases in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224. In some embodiments, the antisense strand has at least 70% (e.g., at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) complementarity to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.
[0010] In some embodiments, the antisense strand has at least 75% complementarity to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224. For example, the antisense strand may have at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementarity to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.
[0011] In some embodiments, the antisense strand has at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0012] In some embodiments, the antisense strand has 10 to 30 contiguous nucleotides (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0013] In some embodiments, the antisense strand has 12 to 30 contiguous nucleotides (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0014] In some embodiments, the antisense strand has 15 to 30 contiguous nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0015] In some embodiments, the antisense strand has 18 to 30 contiguous nucleotides (e.g., 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0016] In some embodiments, the antisense strand has 18 to 25 consecutive nucleotides (e.g., 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0017] In some embodiments, the antisense strand has 18 to 21 consecutive nucleotides (e.g., 18, 19, 20, or 21 consecutive nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0018] In some embodiments, the antisense strand has 21 consecutive nucleotides that are completely complementary to a continuous polynucleotide segment of equal length within a region of the KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437-654 and 1035-1224.
[0019] In some embodiments, the antisense strand has 21 to 30 contiguous nucleotides (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0020] In some embodiments, the antisense strand has 24 to 30 contiguous nucleotides (e.g., 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0021] In some embodiments, the antisense strand has 30 consecutive nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0022] In some embodiments, the antisense strand has 9 or fewer nucleotide mismatches to a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224, and optionally, the antisense strand contains 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or only 1 mismatch to a region of a KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
[0023] In some embodiments of any of the aforementioned aspects or embodiments of the present disclosure, the region of the KCNT1 RNA transcript has any one of the nucleic acid sequences of SEQ ID NOs: 437-654. In some embodiments of any of the aforementioned aspects or embodiments of the present disclosure, the region of the KCNT1 RNA transcript has any one of the nucleic acid sequences of SEQ ID NOs: 437-458, 460, 464-509, 522-560, 563-594, 598-603, 605-654, and 1035-1172. In some embodiments of any of the aforementioned aspects or embodiments of the present disclosure, the region of the KCNT1 RNA transcript has the nucleic acid sequence of SEQ ID NO: 455.
[0024] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-218. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 1-22, 24, 28-73, 86-124, 127-158, 162-167, 169-218, and 655-792. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 19.
[0025] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-218. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 1 to 22, 24, 28 to 73, 86 to 124, 127 to 158, 162 to 167, 169 to 218, and 655 to 792. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 19.
[0026] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NOs: 1-218 and 655-844, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-218 and 655-844. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NOs: 1-218, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-218. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 1-22, 24, 28-73, 86-124, 127-158, 162-167, 169-218, and 655-79, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NO: 1-22, 24, 28-73, 86-124, 127-158, 162-167, 169-218, and 655-79. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:19, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of SEQ ID NO:19.
[0027] In some embodiments, the antisense strand has a nucleic acid sequence of any one of SEQ ID NOs: 1 to 218 and 655 to 844. In some embodiments, the antisense strand has a nucleic acid sequence of any one of SEQ ID NOs: 1 to 218. In some embodiments, the antisense strand has a nucleic acid sequence of any one of SEQ ID NOs: 1 to 22, 24, 28 to 73, 86 to 124, 127 to 158, 162 to 167, 169 to 218, and 655 to 79. In some embodiments, the antisense strand has a nucleic acid sequence of SEQ ID NO: 19.
[0028] In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034. In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 219-436. In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 219-240, 242, 246-291, 304-342, 345-376, 380-385, 387-436, and 845-982. In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:237.
[0029] In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034. In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 219-436. In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 219-240, 242, 246-291, 304-342, 345-376, 380-385, 387-436, and 845-982. In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 237.
[0030] In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 219-436 and 845-1034, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 219-436 and 845-1034. In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 219-436, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 219-436. In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 219-240, 242, 246-291, 304-342, 345-376, 380-385, 387-436, and 845-982, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 219-240, 242, 246-291, 304-342, 345-376, 380-385, 387-436, and 845-982. In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:237, and optionally the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NO:237.
[0031] In some embodiments, the siRNA molecule has a sense strand having any one of the nucleic acid sequences of SEQ ID NOs: 219 to 436 and 845 to 1034. In some embodiments, the siRNA molecule has a sense strand having any one of the nucleic acid sequences of SEQ ID NOs: 219 to 436. In some embodiments, the siRNA molecule has a sense strand having any one of the nucleic acid sequences of SEQ ID NOs: 219 to 240, 242, 246 to 291, 304 to 342, 345 to 376, 380 to 385, 387 to 436, and 845 to 982. In some embodiments, the siRNA molecule has a sense strand having the nucleic acid sequence of SEQ ID NO: 237.
[0032] In some embodiments, the antisense strand has a structure represented by Formula I, which in the 5'-3' direction is: AB-(A') j -CP 2 -DP 1 -(C'-P 1 ) k -C' Formula I; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula CP 2 -DP 2 -DP 2 -DP 2 Represented by; each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0033] In some embodiments, the antisense strand has a structure represented by Formula A1, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAOBOAOBSASASASBSA Formula A1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0034] In some embodiments, the antisense strand has a structure represented by Formula II, which, in the 5'-3' direction, is: AB-(A') j -CP 2 -DP 1 -(CP 1 ) k -C' Formula II; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula CP 2 -DP 2 -DP 2 -DP 2 Represented by; each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0035] In some embodiments, the antisense strand has a structure represented by Formula A2, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAAOBOAOBSASASASASA Formula A2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0036] In some embodiments, the sense strand has a structure represented by Formula III, which, in the 5'-3' direction, is: E-(A') m -F Formula III; In the formula, E is a compound represented by the formula (CP 1 )2; F is the formula (CP 2 )3-DP 1 -CP 1 -C, (CP 2 )3-DP 2 -CP 2 -C, (CP 2 )3-DP 1 -CP 1 -D, or (CP 2 )3-DP 2 -CP 2 - represented by D; A', C, D, P 1 , and P 2 is as defined in formula II; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0037] In some embodiments, the sense strand has a structure represented by formula S1, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBBSASA Formula S1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0038] In some embodiments, the sense strand has a structure represented by formula S2, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOA Formula S2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0039] In some embodiments, the sense strand has a structure represented by formula S3, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBSASB formula S3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0040] In some embodiments, the sense strand has a structure represented by formula S4, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOB Equation S4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0041] In some embodiments, the antisense strand has a structure represented by Formula IV, which, in the 5'-3' direction, is: A-(A') j -CP 2 -B-(CP 1 ) k -C' Formula IV; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula DP 1 -CP 1 -DP 1 Represented by; each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0042] In some embodiments, the antisense strand has a structure represented by Formula A3, which, in the 5'-3' direction, is: ASBSAOBOAOBOAOBOAOBOA-OBOAOBOAOBSASASASA formula A3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0043] In some embodiments, the sense strand has a structure represented by Formula V, where in the 5'-3' direction, Formula V is: E-(A') m -CP 2 -F formula V; In the formula, E is a compound represented by the formula (CP 1 )2; F is the formula DP 1 -CP 1 -C, D.P. 2 -CP 2 -C, D.P. 1 -CP 1 -D, or DP 2 -CP 2 - represented by D; A', C, D, P 1 , and P 2 is as defined in formula IV; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0044] In some embodiments, the sense strand has a structure represented by formula S5, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASA Formula S5; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0045] In some embodiments, the sense strand has a structure represented by formula S6, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOA Formula S6; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0046] In some embodiments, the sense strand has a structure represented by formula S7, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASB Formula S7; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0047] In some embodiments, the sense strand has a structure represented by formula S8, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOB formula S8; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0048] In some embodiments, the antisense strand has a structure represented by Formula VI, which in the 5'-3' direction is: A.B. j -EB k -EFG l -DP1 -C' Formula VI; where A is of the formula CP 1 -DP 1 Represented by; Each B is a function of the formula CP 2 Represented by; each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each E is a function of the formula DP 2 -CP 2 Represented by; F is the formula DP 1 -CP 1 Represented by; Each G has the formula CP 1 Represented by; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); l is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0049] In some embodiments, the antisense strand has a structure represented by Formula A4, which, in the 5'-3' direction, is: ASBSAOAOAOBOAOAOAOAOA-OAOAOBOAOBSASASASBSA formula A4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0050] In some embodiments, the sense strand has a structure represented by Formula VII, which in the 5'-3' direction is: HB m -I n -A'-B o -HC Formula VII; where A' is a compound of the formula CP 2 -DP 2 Represented by; Each H is a function of the formula (CP 1 )2; Each I is independently represented by the formula (DP 2 ) is represented as; B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); n is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); o is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).
[0051] In some embodiments, the sense strand has a structure represented by formula S9, which, in the 5'-3' direction, is: ASASAOAOAOBOBOBOBOAOBOA-OAOAOAASASA Formula S9; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0052] In some embodiments, the antisense strand also has a 5' phosphorus stabilizing moiety at the 5' end of the antisense strand.
[0053] In some embodiments, the sense strand also has a 5' phosphorus stabilizing moiety at the 5' end of the sense strand.
[0054] In some embodiments, each 5' phosphorus stabilizing moiety is independently represented by any one of formulas IX, XX, XI, XII, XIII, XIV, XV, or XVI. [ka] wherein Nuc represents a nucleobase, optionally the nucleobase is selected from the group consisting of adenine, uracil, guanine, thymine, and cytosine, and R represents an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, phenyl, benzyl, a cation (e.g., a monovalent cation), or hydrogen.
[0055] In some embodiments, the nucleobase is adenine, uracil, guanine, thymine, or cytosine.
[0056] In some embodiments, the 5' phosphorus stabilizing moiety is an (E)-vinyl phosphonate of formula XI.
[0057] In some embodiments, the siRNA molecule also has a hydrophobic portion at the 5' or 3' end of the siRNA molecule.
[0058] In some embodiments, the hydrophobic moiety is selected from the group consisting of cholesterol, vitamin D, or tocopherol.
[0059] In some embodiments, the siRNA molecule is a branched siRNA molecule.
[0060] In some embodiments, the branched siRNA molecule is biantennary, triantennary, or tetraantennary.
[0061] In some embodiments, the siRNA molecule is biantennary, and optionally the biantennary siRNA molecule is represented by any one of Formulas XVII, XVIII, or XIX: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
[0062] In some embodiments, the biantennary siRNA molecule is represented by formula XVII. In some embodiments, the biantennary siRNA molecule is represented by formula XVIII. In some embodiments, the biantennary siRNA molecule is represented by formula XIX.
[0063] In some embodiments, the siRNA molecule is tri-antennary, and optionally the tri-antennary siRNA molecule is represented by any one of Formulas XX, XXI, XXII, or XXIII: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
[0064] In some embodiments, the three-branched siRNA molecule is represented by formula XX. In some embodiments, the three-branched siRNA molecule is represented by formula XXI. In some embodiments, the three-branched siRNA molecule is represented by formula XXII. In some embodiments, the three-branched siRNA molecule is represented by formula XXIII.
[0065] In some embodiments, the siRNA molecule is tetraantennary, and optionally the tetraantennary siRNA molecule is represented by any one of Formulas XXIV, XXV, XXVI, XXVII, or XXVIII: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
[0066] In some embodiments, the four-branched siRNA molecule is represented by formula XXIV. In some embodiments, the four-branched siRNA molecule is represented by formula XXV. In some embodiments, the four-branched siRNA molecule is represented by formula XXVI. In some embodiments, the four-branched siRNA molecule is represented by formula XXVII. In some embodiments, the four-branched siRNA molecule is represented by formula XXVIII.
[0067] In some embodiments of the branched siRNA, the linker is selected from the group consisting of one or more consecutive subunits of ethylene glycol (e.g., polyethylene glycol (PEG), e.g., triethylene glycol (TrEG) or tetraethylene glycol (TEG)), alkyl, carbohydrate, block copolymer, peptide, RNA, and DNA.
[0068] In some embodiments, the linker is an ethylene glycol oligomer. In some embodiments, the linker is an alkyl oligomer. In some embodiments, the linker is a carbohydrate oligomer. In some embodiments, the linker is a block copolymer. In some embodiments, the linker is a peptide oligomer. In some embodiments, the linker is an RNA oligomer. In some embodiments, the linker is a DNA oligomer.
[0069] In some embodiments, the ethylene glycol oligomer is PEG. In some embodiments, the PEG is TrEG. In some embodiments, the PEG is TEG.
[0070] In some embodiments, the oligomer or copolymer contains between 2 and 20 consecutive subunits (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive subunits).
[0071] In some embodiments, the linker joins one or more (eg, 1, 2, 3, 4, or more) siRNA molecules via a covalent bond-forming moiety.
[0072] In some embodiments, the covalent bond forming moiety is selected from the group consisting of alkyl, ester, amide, carbamate, phosphonate, phosphate, phosphorothioate, phosphoramidate, triazole, urea, and formacetal.
[0073] In some embodiments, the linker comprises a structure of formula L1. [ka]
[0074] In some embodiments, the linker comprises a structure of formula L2. [ka]
[0075] In some embodiments, the linker comprises a structure of formula L3. [ka]
[0076] In some embodiments, the linker comprises a structure of formula L4. [ka]
[0077] In some embodiments, the linker comprises a structure of formula L5. [ka]
[0078] In some embodiments, the linker comprises a structure of formula L6. [ka]
[0079] In some embodiments, the linker comprises a structure of formula L7. [ka]
[0080] In some embodiments, the linker comprises a structure of formula L8. [ka]
[0081] In some embodiments, the linker comprises a structure of formula L9. [ka]
[0082] In some embodiments of any of the siRNA molecules described herein, 50% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109, 104, 105, 106, 107, 108, 109 ... %, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% can be 2'-O-Me ribonucleotides.
[0083] In some embodiments, 60% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).
[0084] In some embodiments, 70% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).
[0085] In some embodiments, 80% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).
[0086] In some embodiments, 90% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).
[0087] In some embodiments, 10% or less of the internucleoside linkages are phosphodiester or phosphorothioate linkages. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the internucleoside linkages are phosphodiester or phosphorothioate linkages. In some embodiments, 100% of the internucleoside linkages are phosphodiester or phosphorothioate linkages.
[0088] In some embodiments, 9 of the internucleoside linkages are phosphodiester or phosphorothioate linkages.
[0089] In some embodiments, the length of the antisense strand is between 10 and 30 nucleotides (e.g., 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), between 15 and 25 nucleotides (e.g., 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides), or between 18 and 23 nucleotides (e.g., 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the length of the antisense strand is 20 nucleotides. In some embodiments, the length of the antisense strand is 21 nucleotides. In some embodiments, the length of the antisense strand is 22 nucleotides. In some embodiments, the length of the antisense strand is 23 nucleotides. In some embodiments, the length of the antisense strand is 24 nucleotides. In some embodiments, the length of the antisense strand is 25 nucleotides. In some embodiments, the length of the antisense strand is 26 nucleotides. In some embodiments, the length of the antisense strand is 27 nucleotides. In some embodiments, the length of the antisense strand is 28 nucleotides. In some embodiments, the length of the antisense strand is 29 nucleotides. In some embodiments, the length of the antisense strand is 30 nucleotides.
[0090] In some embodiments, the siRNA molecules of the branched compound are linked together by a linker (e.g., ethylene glycol oligomer, such as tetraethylene glycol). In some embodiments, the siRNA molecules of the branched compound are linked together via a linker between the sense strand of one siRNA molecule and the sense strand of the other siRNA molecule. In some embodiments, the siRNA molecules are linked together via a linker between the antisense strand of one siRNA molecule and the antisense strand of the other siRNA molecule. In some embodiments, the siRNA molecules of the branched compound are linked together via a linker between the sense strand of one siRNA molecule and the antisense strand of the other siRNA molecule.
[0091] In some embodiments, the length of the sense strand is between 12 and 30 nucleotides (e.g., 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), or between 14 and 18 nucleotides (e.g., 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, or 18 nucleotides). In some embodiments, the length of the sense strand is 15 nucleotides. In some embodiments, the length of the sense strand is 16 nucleotides. In some embodiments, the length of the sense strand is 17 nucleotides. In some embodiments, the length of the sense strand is 18 nucleotides. In some embodiments, the length of the sense strand is 19 nucleotides. In some embodiments, the length of the sense strand is 20 nucleotides. In some embodiments, the length of the sense strand is 21 nucleotides. In some embodiments, the length of the sense strand is 22 nucleotides. In some embodiments, the sense strand is 23 nucleotides in length. In some embodiments, the sense strand is 24 nucleotides in length. In some embodiments, the sense strand is 25 nucleotides in length. In some embodiments, the sense strand is 26 nucleotides in length. In some embodiments, the sense strand is 27 nucleotides in length. In some embodiments, the sense strand is 28 nucleotides in length. In some embodiments, the sense strand is 29 nucleotides in length. In some embodiments, the sense strand is 30 nucleotides in length.
[0092] In some embodiments, the four internucleoside linkages are phosphorothioate linkages.
[0093] In some embodiments of the siRNA molecules described herein, the antisense strand is 18 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 20 nucleotides long.In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 14 nucleotides long.In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 22 nucleotides long.In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 17 nucleotides long.In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 25 nucleotides long.In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 14 nucleotides long.In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 29 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 16 nucleotides long.In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 29 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 30 nucleotides long.
[0094] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an siRNA molecule of any of the preceding aspects or embodiments of the present disclosure and a pharma- ceutically acceptable excipient, carrier, or diluent.
[0095] In a further aspect, the present disclosure provides a method of delivering an siRNA molecule to the CNS of a subject diagnosed with an epilepsy syndrome by administering to the subject a therapeutically effective amount of an siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the present disclosure.
[0096] In a further aspect, the present disclosure provides a method of treating an epilepsy syndrome in a subject in need thereof by administering to the CNS of the subject a therapeutically effective amount of a siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the present disclosure.
[0097] In some embodiments, the epilepsy syndrome is frontal lobe epilepsy, occipital lobe epilepsy, mesial temporal lobe epilepsy, parietal lobe epilepsy, benign myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, Lennox-Gastaut syndrome, West syndrome, sleep-related hyperkinetic epilepsy, progressive myoclonic epilepsy, febrile seizures, epilepsy with persistent spike-and-wave during slow-wave sleep, Landau-Kleffner syndrome, Rasmussen syndrome, epilepsy due to inborn errors of metabolism, infantile epilepsy with migrating focal seizures, autosomal dominant nocturnal frontal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and / or multifocal epilepsy.
[0098] In another aspect, the present disclosure provides a method for reducing KCNT1 expression in a subject in need thereof by administering a therapeutically effective amount of an siRNA or pharmaceutical composition of any of the preceding aspects or embodiments of the present disclosure.
[0099] In some embodiments, upon administration of an siRNA molecule or pharmaceutical composition of any of the aforementioned aspects or embodiments of the present disclosure, the subject exhibits selective reduction in KCNT1 expression compared to reduction in expression of one or more other voltage-gated potassium ion channels.
[0100] In some embodiments, the siRNA molecule or pharmaceutical composition is administered to the subject by intracerebroventricular or intrathecal injection.
[0101] In some embodiments, the subject is a human.
[0102] In another aspect, the present disclosure provides a kit comprising an siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the disclosure and a package insert instructing a user of the kit to carry out a method of any of the preceding aspects or embodiments of the disclosure. [Brief description of the drawings]
[0103] [Figure 1] 1 is a graph showing IC50 determination of an exemplary siRNA molecule of the disclosure having an antisense strand of SEQ ID NO: 19 and a sense strand of SEQ ID NO: 237. The IC50 was determined to be 0.0415 nM.
[0104] definition Unless otherwise defined herein, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In case of any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definitions. Unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular. The use of "or" means "and / or" unless otherwise stated. The use of the term "including" as well as other forms such as "include" and "included" are not limiting.
[0105] As used herein, the term "nucleic acid" refers to an RNA or DNA molecule composed of a chain of ribonucleotides or deoxyribonucleotides, respectively.
[0106] As used herein, the term "therapeutic nucleic acid" refers to a nucleic acid molecule (e.g., a ribonucleic acid) that has partial or complete complementarity with, interacts with, and mediates the silencing of expression of a disease-associated target mRNA.
[0107] As used herein, the term "carrier nucleic acid" refers to a nucleic acid molecule (e.g., a ribonucleic acid) that has sequence complementarity with and hybridizes to a therapeutic nucleic acid. As used herein, the term "3' end" refers to the end of a nucleic acid that contains an unmodified hydroxyl group at the 3' carbon of the ribose ring.
[0108] As used herein, the term "nucleoside" refers to a molecule that consists of a heterocyclic base and its sugar.
[0109] As used herein, the term "nucleotide" refers to a nucleoside having a phosphate group or variant thereof at its 3' or 5' sugar hydroxyl group. Examples of phosphate group variants include, but are not limited to, saturated alkyl phosphonates, unsaturated alkenyl phosphonates, phosphorothioates, and phosphoramidites.
[0110] In the context of the present invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages, as well as oligonucleotides having non-naturally occurring (e.g., modified) portions that function similarly. Such modified or substituted oligonucleotides are often preferred over native forms due to desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid targets, and increased stability in the presence of nucleases.
[0111] As used herein, the term "siRNA" refers to small interfering RNA duplexes that induce the RNA interference (RNAi) pathway. siRNA molecules may be of various lengths (generally 10-30 base pairs) and may contain various degrees of complementarity to their target mRNA. The term "siRNA" includes duplexes of two separate strands, and single strands that optionally form a hairpin structure containing a double-stranded region.
[0112] As used herein, the term "antisense strand" refers to the strand of the siRNA duplex that contains a degree of complementarity to a target gene.
[0113] As used herein, the term "sense strand" refers to the siRNA duplex that contains complementarity to the antisense strand.
[0114] The term "interfering RNA molecule" refers to an RNA molecule, such as a small interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA (shRNA), or antisense oligonucleotide (ASO), that inhibits the endogenous function of a target RNA transcript.
[0115] As used herein, the terms "express" and "expression" refer to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing); and (3) translation of the RNA into a polypeptide or protein. In the context of a gene that encodes a protein product, terms such as "gene expression" are used interchangeably with terms such as "protein expression." Expression of a gene or protein of interest in a patient can be determined, for example, by detecting, in a sample obtained from the patient, an increase in the amount or concentration of mRNA encoding the corresponding protein (e.g., assessed using RNA detection procedures described herein or known in the art, such as quantitative polymerase chain reaction (qPCR) and RNA seq techniques), an increase in the amount or concentration of the corresponding protein (e.g., assessed using protein detection methods described herein or known in the art, such as enzyme-linked immunosorbent assay (ELISA), among others), and / or an increase in the activity of the corresponding protein (e.g., in the case of an enzyme, assessed using enzyme activity assays described herein or known in the art). As used herein, a cell is considered to "express" a gene or protein of interest if one or more, or all of the above events are detectable within the cell or in the medium in which the cell resides. For example, a gene or protein of interest is considered to be "expressed" by a cell, or population of cells, if it is possible to detect: (i) production of a corresponding RNA transcript, such as an mRNA template, by the cell, or population of cells (e.g., using the RNA detection procedures described herein); (ii) processing of the RNA transcript (e.g., splicing, editing, 5' capping, and / or 3' end processing, using the RNA detection procedures described herein); (iii) translation of the RNA template into a protein product (e.g., using the protein detection procedures described herein); and / or (iv) post-translational modification of the protein product (e.g., using the protein detection procedures described herein).
[0116] As used herein, the terms "target," "targeting," and "targeted" in the context of siRNA design refer to generating an antisense strand such that it anneals within a region within an mRNA transcript of interest in a manner that reduces translation of the mRNA into a protein product.
[0117] As used herein, the terms "chemically modified nucleotide," "nucleotide analog," "altered nucleotide," and "modified nucleotide" refer to non-standard nucleotides, including non-naturally occurring ribonucleotides or deoxyribonucleotides. Exemplary nucleotide analogs are modified at any position such that certain chemical properties of the nucleotide are altered while retaining the ability of the nucleotide analog to perform its intended function.
[0118] As used herein, the term "metabolically stabilized" refers to an RNA molecule that contains chemically modified ribonucleotides to reduce the metabolic rate of the RNA molecule administered to a subject. Exemplary modifications include 2'-hydroxy to 2'-O-methoxy or 2'-fluoro, and phosphodiester to phosphorothioate.
[0119] As used herein, the term "phosphorothioate" refers to a phosphate group of a nucleotide that is modified by replacing one or more of the oxygens of the phosphate group with sulfur.
[0120] As used herein, the terms "internucleoside" and "internucleotide" refer to the linkage between a nucleoside and a nucleotide, respectively.
[0121] As used herein, the term "antagomir" refers to a nucleic acid that can function as an inhibitor of miRNA activity.
[0122] As used herein, the term "gapmer" refers to a chimeric antisense nucleic acid that contains a central block of deoxynucleotide monomers of sufficient length to induce RNase H cleavage. The deoxynucleotide block is flanked by ribonucleotide monomers or ribonucleotide monomers containing modifications.
[0123] As used herein, the term "mixmer" refers to a nucleic acid composed of a mixture of locked nucleic acid (LNA) and DNA.
[0124] As used herein, the term "guide RNA" refers to a nucleic acid that has sequence complementarity to a specific sequence in a genome immediately upstream or one base pair upstream of a protospacer adjacent motif (PAM) sequence used in the CRISPR / Cas9 gene editing system. Alternatively, "guide RNA" may refer to a nucleic acid that has sequence complementarity (e.g., is antisense) to a specific messenger RNA (mRNA) sequence. In this context, a guide RNA may also have sequence complementarity to a "passenger RNA" sequence of equal or shorter length that is identical or substantially identical to the sequence of the mRNA to which the guide RNA hybridizes.
[0125] As used herein, the term "branched siRNA" refers to a compound that contains two or more double-stranded siRNA molecules that are covalently linked to each other.Branched siRNA molecules can be "bi-branched", also referred to herein as "di-siRNA", where this siRNA molecule comprises two siRNA molecules that are covalently linked to each other, for example, via a linker.Branched siRNA molecules can be "tri-branched", also referred to herein as "tri-siRNA", where this siRNA molecule comprises three siRNA molecules that are covalently linked to each other, for example, via a linker.Branched siRNA molecules can be "four-branched", also referred to herein as "tetra-siRNA", where this siRNA molecule comprises four siRNA molecules that are covalently linked to each other, for example, via a linker.
[0126] As used herein, the term "branch point moiety" refers to the chemical moiety of the branched siRNA structure of the present disclosure, which can be covalently attached to the 5'-end or 3'-end of the antisense or sense strand of siRNA molecule, and can support the attachment of additional single-stranded or double-stranded siRNA molecules.Non-limiting examples of branch point moieties suitable for use with the disclosed methods and compositions include, for example, phosphoramidite, tosylated solketal, 1,3-diaminopropanol, pentaerythritol, and any one of the branch point moieties described in US Patent No. 10,478,503.
[0127] The term "phosphate moiety" as used herein refers to a terminal phosphate group, including phosphate and modified phosphates. The phosphate moiety may be located at either terminus, but is preferred at the 5'-terminal nucleoside. In one aspect, the terminal phosphate has the formula -OP(=O)(OH)OH and is unmodified. In another aspect, the terminal phosphate is modified such that one or more of the O and OH groups are replaced with H, O, S, N(R'), or an alkyl where R' is H, an amino protecting group, or an unsubstituted or substituted alkyl. In some embodiments, the 5' and or 3' terminal groups can each independently comprise 1-3 phosphate moieties that are unmodified (diphosphate or triphosphate) or modified.
[0128] As used herein, the term "5' phosphorus stabilizing moiety" refers to a terminal phosphate group, including phosphate as well as modified phosphates (e.g., phosphorothioates, phosphodiesters, phosphonates). The phosphate moiety may be located at either terminus, but is preferred at the 5' terminal nucleoside. In one aspect, the terminal phosphate has the formula -OP(=O)(OH)OH and is unmodified. In another aspect, the terminal phosphate is modified such that one or more of the O and OH groups are replaced with H, O, S, N(R'), or an alkyl where R' is H, an amino protecting group, or an unsubstituted or substituted alkyl. In some embodiments, the 5' and or 3' terminal groups can each independently comprise one to three phosphate moieties that are unmodified (diphosphate or triphosphate) or modified.
[0129] The phosphate group of a nucleotide may also be modified, for example, by replacing one or more oxygens of the phosphate group with sulfur (e.g., phosphorothioate), or by making other substitutions that allow the nucleotide to perform its intended function, as described, for example, in Eckstein, Antisense Nucleic Acid Drug Dev. 10:117-21, 2000; Rusckowski et al., Antisense Nucleic Acid Drug Dev. 10:333-45, 2000; Stein, Antisense Nucleic Acid Drug Dev. 11:317-25, 2001; Vorobjev et al., Antisense Nucleic Acid Drug Dev. 11:77-85, 2001; and US5,684,143. Certain of the above-referenced modifications (e.g., phosphate group modifications) preferably reduce, for example, the hydrolysis rate of a polynucleotide that contains the analog in vivo or in vitro.
[0130] As used herein, the term "complementary" refers to two nucleotides that form a canonical Watson-Crick base pair. For the avoidance of doubt, in the context of this disclosure, Watson-Crick base pairs include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. In this context, proper Watson-Crick base pairs are referred to as "matches," while the respective unpaired and improperly paired nucleotides are referred to as "mismatches." Alignment for purposes of determining percent nucleic acid sequence complementarity can be accomplished in a variety of ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software.
[0131] "Percent sequence complementarity" to a reference polynucleotide sequence is defined as the percentage of nucleic acids in a candidate sequence that are complementary to nucleic acids in the reference polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence complementarity. A given nucleotide is considered to be "complementary" to a reference nucleotide as described herein if the two nucleotides form a standard Watson-Crick base pair. For the avoidance of doubt, in the context of the present disclosure, Watson-Crick base pairs include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. In this context, a proper Watson-Crick base pair is referred to as a "match," while each unpaired nucleotide and an improperly paired nucleotide are referred to as a "mismatch." Alignment for purposes of determining percent nucleic acid sequence complementarity can be accomplished in a variety of ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum complementarity over the entire length of the sequences being compared. By way of illustration, the percent sequence complementarity of a given nucleic acid sequence A to a given nucleic acid sequence B (which can alternatively be referred to as a given nucleic acid sequence A having a certain percent complementarity to a given nucleic acid sequence B) is calculated as follows: 100×(fraction X / Y) where X is the number of complementary base pairs in a program alignment of A and B (e.g., as performed by computer software such as BLAST) and Y is the total number of nucleic acids in B. It is understood that if the length of nucleic acid sequence A is not equal to the length of nucleic acid sequence B, then the percent sequence complementarity to B is not equal to the percent sequence complementarity of B to A. As used herein, a query nucleic acid sequence is considered to be "fully complementary" to a reference nucleic acid sequence if the query nucleic acid sequence has 100% sequence complementarity to the reference nucleic acid sequence.
[0132] "Percent sequence identity" with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to those in a reference polynucleotide or polypeptide sequence after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity. Alignment for the purpose of determining percent sequence identity of nucleic acids or amino acids can be achieved in a variety of ways that are within the capabilities of those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared. For example, percent sequence identity values can be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence A to, with, or against a given nucleic acid or amino acid sequence B (which may alternatively be referred to as a given nucleic acid or amino acid sequence A having a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence B) is calculated as follows: 100×(fraction X / Y) where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in a programmatic alignment of A and B, and Y is the total number of nucleic acids in B. If the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, then the percent sequence identity of A to B will not be equal to the percent sequence identity of B to A.
[0133] The term "sufficiently complementary to hybridize" as used herein refers to a nucleic acid sequence or a portion thereof that does not have to be fully complementary (e.g., 100% complementary) to a target region or a nucleic acid sequence or a portion thereof, which has one or more nucleotide mismatches with the target region but can still hybridize to the target region under specified conditions. For example, a nucleic acid can be, for example, 95% complementary, 90% complementary, 85% complementary, 80% complementary, 75% complementary, 70% complementary, 65% complementary, 60% complementary, 55% complementary, 50% complementary, or less, but still form sufficient base pairs with the target to hybridize over its entire length.
[0134] Nucleic acid "hybridization" or "annealing" is achieved when one or more nucleoside residues within a polynucleotide base pair with one or more complementary nucleosides to form a stable duplex. Base pairing is usually caused by hydrogen bonding events. Hybridization includes Watson-Crick base pairs formed from natural and / or modified nucleobases. Hybridization may also include non-Watson-Crick base pairs, such as wobble base pairs (guanosine-uracil, hypoxanthine-uracil, hypoxanthine-adenine, and hypoxanthine-cytosine) and Hoogsteen base pairs. Nucleic acids do not need to be 100% complementary to undergo hybridization. For example, one nucleic acid can be, e.g., 95% complementary, 90% complementary, 85% complementary, 80% complementary, 75% complementary, 70% complementary, 65% complementary, 60% complementary, 55% complementary, 50% complementary, or less, to another nucleic acid, yet the two nucleic acids can form sufficient base pairs with each other to hybridize.
[0135] A "stable duplex" formed upon annealing / hybridization of one nucleic acid to another is a duplex structure that is not denatured by harsh washing. Exemplary harsh washing conditions are known in the art and include temperatures about 5°C below the melting temperatures of the individual strands of the duplex and low concentrations of monovalent salt, such as monovalent salt concentrations (e.g., NaCl concentrations) of less than 0.2M (0.2M, 0.19M, 0.18M, 0.17M, 0.16M, 0.15M, 0.14M, 0.13M, 0.12M, 0.11M, 0.1M, 0.09M, 0.08M, 0.07M, 0.06M, 0.05M, 0.04M, 0.03M, 0.02M, 0.01M, or lower).
[0136] The term "gene silencing" refers to the suppression of gene expression, for example, the endogenous gene expression of KCNT1, which can be mediated through the process of affecting transcription and / or the process of affecting post-transcriptional mechanisms.In some embodiments, gene silencing occurs when RNAi molecules initiate the inhibition or degradation of the mRNA transcribed from the target gene in a sequence-specific manner through RNA interference, thereby preventing the translation of the product of the gene.
[0137] As used herein, the term "overactive disease driver gene" refers to a gene with increased activity and / or expression that contributes to or causes a disease state in a subject (e.g., a human). The disease state may be caused or exacerbated by the overactive disease driver gene directly, or by an intermediary gene(s).
[0138] As used herein, the term "ethylene glycol chain" refers to a carbon chain having the formula ((CH2OH)2).
[0139] As used herein, "alkyl" refers to a saturated hydrocarbon group. Alkyl groups can be acyclic or cyclic and, if unsubstituted, contain only C and H. When naming an alkyl residue with a specific number of carbons, all geometric isomers with that number of carbons are intended to be encompassed and described. Thus, for example, "butyl" is meant to include n-butyl, sec-butyl, and iso-butyl. Examples of alkyl include ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. In some embodiments, alkyl can be substituted. Suitable substituents that can be introduced into alkyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.
[0140] As used herein, "alkenyl" refers to an acyclic or cyclic unsaturated hydrocarbon group having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C). Alkenyl groups, when unsubstituted, contain only C and H. When an alkenyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed and described. Thus, for example, "butenyl" is meant to include n-butenyl, sec-butenyl, and iso-butenyl. Examples of alkenyl include -CH=CH2, -CH2-CH=CH2, and -CH2-CH=CH-CH=CH2. In some embodiments, alkenyl can be substituted. Suitable substituents that can be introduced into alkenyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.
[0141] As used herein, "alkynyl" refers to an acyclic or cyclic unsaturated hydrocarbon group having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C). Alkynyl groups contain only C and H when unsubstituted. When an alkynyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed and described. Thus, for example, "pentynyl" is meant to include n-pentynyl, sec-pentynyl, and iso-pentynyl. Examples of alkynyl include -C≡CH and -C≡C-CH3. In some embodiments, alkynyl can be substituted. Suitable substituents that can be introduced into alkynyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.
[0142] As used herein, the term "phenyl" refers to a monocyclic arene having one hydrogen atom removed from a carbon atom of the ring. A phenyl group can be unsubstituted or substituted with one or more suitable substituents, which substitute for the H of the phenyl group.
[0143] As used herein, the term "benzyl" refers to the monovalent radical obtained when the hydrogen atom attached to the methyl group of toluene is removed. Benzyl generally has the formula phenyl-CH2-. A benzyl group can be unsubstituted or substituted with one or more suitable substituents. For example, a substituent may replace an H in the phenyl moiety and / or an H in the methylene (-CH2-) moiety.
[0144] As used herein, the term "amide" refers to an alkyl, alkenyl, alkynyl, or aromatic group bound to an aminocarbonyl functional group.
[0145] As used herein, the term "triazole" refers to a heterocyclic compound having the formula (C2H3N3) that has a five-membered ring of two carbons and three nitrogens, the positions of which can vary to give rise to multiple isomers.
[0146] As used herein, the term "end group" refers to the group at which a carbon chain or nucleic acid ends.
[0147] As used herein, "amino acid" refers to a molecule that contains an amine and a carboxyl functional group as well as a side chain characteristic of an amino acid.
[0148] In some embodiments, the amino acid is selected from the group of proteinogenic amino acids. In some embodiments, the amino acid is an L-amino acid or a D-amino acid. In some embodiments, the amino acid is a synthetic amino acid (e.g., a beta-amino acid).
[0149] As used herein, the term "lipophilic amino acid" refers to an amino acid that contains a hydrophobic moiety (eg, an alkyl chain or an aromatic ring).
[0150] As used herein, the term "delivery target" refers to an organ or part of the body to which it is desired to deliver a branched oligonucleotide composition.
[0151] As used herein, the term "between X and Y" is inclusive of values of X and Y. For example, "between X and Y" refers to a range of values between a value of X and a value of Y, as well as a value of X and a value of Y.
[0152] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism, such as a mammal (e.g., a human), that experiences epilepsy episodes and / or epilepsy-related phenotypes (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, cardiac arrhythmias, etc.) and / or contains a gain-of-function KCNT1 variant allele. Non-limiting examples of subjects and patients diagnosed with epilepsy include subjects and patients diagnosed with infantile epilepsy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, leukodystrophy and / or leukoencephalopathy, focal epilepsy, and multifocal epilepsy.
[0153] As used herein, the term "epilepsy" refers to any of the various types of epilepsy syndromes, including, but not limited to, frontal lobe epilepsy, occipital lobe epilepsy, mesial temporal lobe epilepsy, parietal lobe epilepsy, benign myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, Lennox-Gastaut syndrome, West syndrome, sleep-related hyperkinetic epilepsy, progressive myoclonic epilepsy, febrile seizures, epilepsy with persistent spike-and-wave during slow-wave sleep, Landau-Kleffner syndrome, Rasmussen syndrome, epilepsy due to inborn errors of metabolism, infantile epilepsy with moving focal seizures, autosomal dominant nocturnal frontal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and / or multifocal epilepsy.
[0154] As used herein, the term "KCNT1" refers to the sodium-activated potassium channel subfamily T member 1 (SLACK, K NaKCNT1 refers to the gene encoding KCNT1 (also called Slo1.1, Slo2.2, and Slo3.1), including any native KCNT1 gene from any source. This term encompasses "full-length" unprocessed KCNT1, and any form of KCNT1 resulting from processing in cells. This term also encompasses naturally occurring variants of KCNT1, such as splice variants or allelic variants. The nucleic acid sequence of an exemplary KCNT1 gene is shown in European Nucleotide Archive (ENA) Accession No. KP869068.1. The amino acid sequence of an exemplary protein encoded by the KCNT1 gene is shown in UNIPROT™ Accession No. Q5JUK3.
[0155] As used herein, the terms "treat", "treated" and "treating" refer to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent, improve or slow (alleviate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical outcome. Beneficial or desired clinical outcomes include, but are not limited to, a reduction in the patient's dependency on anticonvulsant medication; relief of symptoms; a decrease in the severity of the condition, disorder or disease; stabilization (i.e., not worsening) of the condition, disorder or disease, a delay or slowing of the progression of the condition, disorder or disease; an improvement or remission (whether partial or complete) of the condition, disorder or disease, whether detectable or undetectable; an improvement in at least one measurable physical parameter, not necessarily recognized by the patient; or an improvement or amelioration of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without an excessive level of side effects. Treatment also includes prolonging survival compared to the expected survival if not receiving treatment.
[0156] As used herein, the terms "benefit" and "response" are used interchangeably in the context of a subject undergoing therapy for the treatment of epilepsy, for example.For example, the clinical benefit in the context of a subject administered with the siRNA molecule or siRNA composition of the present disclosure includes, but is not limited to, reduced dependence on or complete withdrawal from anticonvulsants, sedatives, and / or neuralgia drugs, and / or; reduced duration and / or frequency of epileptic events experienced by the subject; and / or reduced epilepsy-related phenotypes (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, cardiac arrhythmia, etc.), and / or; reduced wild-type KCNT1 transcript, mutant KCNT1 transcript, variant KCNT1 transcript, splice isoform of KCNT1 transcript, and / or reduced overexpressed KCNT1 transcript. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0157] The present disclosure provides compositions of small interfering RNA (siRNA) molecules having sequence homology with the sodium-activated potassium channel subfamily T member 1 (KCNT1) gene, and methods for administering said siRNA molecules to the central nervous system of a subject. Furthermore, the siRNA molecules described herein may be configured as branched siRNA structures, such as biantennary, triantennary, and tetraantennary, and may further include specific patterns of chemical modifications (e.g., 2' ribose modifications or internucleoside linkage modifications) to improve resistance to nuclease enzymes, toxicity profiles, and physicochemical properties (e.g., thermal stability). Small interfering RNA molecules are short double-stranded RNA molecules. They can mediate RNA interference (RNAi) by degrading mRNAs with complementary nucleotide sequences, thus preventing the translation of target genes.
[0158] The siRNA molecules of the present disclosure can be used to bind, for example, voltage-dependent potassium ions (K + In particular, any of the oligonucleotides disclosed herein may exhibit potent gene-specific inhibition of KCNT1 compared to other genes in the KCNT1 channel family. +It does not contain seed siRNA sequences matching the channel genes KCNT2 and KCNMA1, the cardiac KCNH2, KCNQ1, KCNE1, and KCNE2 genes, or genes in the KCNA, KCNB, KCNC, KCND, KCNQ, KCNV, or KCNH families, which are associated with adverse neurological or other outcomes, usually due to loss-of-function genetic variants.
[0159] The siRNA molecule of the present disclosure can be characterized by an antisense strand having a nucleic acid sequence that is complementary to a region in a KCNT1 mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 437 to 654 and 1035 to 1224. The degree of complementarity of the antisense strand to the region of the KCNT1 mRNA transcript can be sufficient for the antisense strand to anneal over the entire length of the region of the KCNT1 mRNA transcript. For example, the antisense strand can have a nucleic acid sequence that is at least 60% complementary (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to a region of the KCNT1 mRNA transcript.
[0160] In some embodiments, the siRNA molecule of the present disclosure is characterized by an antisense strand having a nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844, or a nucleic acid sequence that is at least 60% identical thereto. For example, the siRNA molecules of the present disclosure can be characterized as having an antisense strand having a nucleic acid sequence that is at least 60% identical (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844.
[0161] In some embodiments, the siRNA molecules of the present disclosure are characterized by a sense strand having a nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034, or a nucleic acid sequence at least 60% identical thereto. For example, a siRNA molecule of the present disclosure can be characterized as having a sense strand having a nucleic acid sequence that is at least 60% identical (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034.
[0162] Exemplary siRNA molecules of the present disclosure are shown below in Table 1. Table 1 summarizes the antisense strand, the sense strand, and the corresponding region of the KCNT1 mRNA transcript targeted by each antisense strand.
[0163] [Table 1-1]
Table 1-2
Table 1-3
Table 1-4
Table 1-5
Table 1-6
Table 1-7
Table 1-8
Table 1-9
Table 1-10
Table 1-11
Table 1-12
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
Table 1-20
Table 1-21
Table 1-22
Table 1-23
Table 1-24
Table 1-25
Table 1-26
Table 1-27
Table 1-28
Table 1-29
Table 1-30
Table 1-31
Table 1-32
Table 1-33
Table 1-34
Table 1-35
[0164] siRNA structure The siRNA molecule of the present disclosure may be in the form of a single-stranded (ss) or double-stranded (ds) oligonucleotide structure. In some embodiments, the siRNA molecule may be a biantennary, triantennary, or tetraantennary molecule. In addition, the siRNA molecule of the present disclosure may contain one or more phosphodiester internucleoside linkages and / or their analogs, such as phosphorothioate internucleoside linkages. The siRNA molecule of the present disclosure may further contain chemically modified nucleosides with 2' sugar modifications.
[0165] The simplest siRNA consists of a ribonucleic acid containing a ss- or ds-structure, formed by a first strand (i.e., antisense strand) and, in the case of ds-siRNA, by a second strand (i.e., sense strand). The first strand comprises a stretch of consecutive nucleotides that is at least partially complementary to the target nucleic acid. The second strand also comprises a stretch of consecutive nucleotides, the second stretch being at least partially identical to the target nucleic acid. The first strand and said second strand can hybridize to each other to form a double-stranded structure. Hybridization typically occurs by Watson-Crick base pairing.
[0166] Depending on the sequence of the first and second strand, hybridization or base pairing is not necessarily complete or perfect, which means that the first and second strands are not 100% base paired due to mismatch.One or more mismatches can also exist in the double strand, without necessarily affecting the RNAi activity of siRNA.
[0167] The first strand comprises a stretch of contiguous nucleotides essentially complementary to the target nucleic acid. Typically, the target nucleic acid sequence is ss-RNA, preferably mRNA, according to the mode of action of the interfering ribonucleic acid. Such hybridization most likely occurs via Watson-Crick base pairing, but is not necessarily limited thereto. The extent to which the first strand has a complementary stretch of contiguous nucleotides to the target nucleic acid sequence can be 80% to 100%, for example, 80%, 85%, 90%, 95%, or 100% complementary.
[0168] The siRNA molecules described herein may employ modifications to the nucleobases, phosphate backbone, ribose core, 5' and 3' ends, and branching, where multiple strands of the siRNA may be covalently linked.
[0169] Length of the small interfering RNA molecule Within the scope of the present invention, any length known in the art and previously unknown can be employed for the present invention. As described herein, the potential length of the antisense strand of the siRNA molecule of the present disclosure is between 10 and 30 nucleotides (e.g., 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), between 15 and 25 nucleotides (e.g., 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides), or between 18 and 23 nucleotides (e.g., 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the antisense strand is 20 nucleotides. In some embodiments, the antisense strand is 21 nucleotides. In some embodiments, the antisense strand is 22 nucleotides. In some embodiments, the antisense strand is 23 nucleotides. In some embodiments, the antisense strand is 24 nucleotides. In some embodiments, the antisense strand is 25 nucleotides. In some embodiments, the antisense strand is 26 nucleotides. In some embodiments, the antisense strand is 27 nucleotides. In some embodiments, the antisense strand is 28 nucleotides. In some embodiments, the antisense strand is 29 nucleotides. In some embodiments, the antisense strand is 30 nucleotides.
[0170] In some embodiments, the sense strand of the siRNA molecules of the present disclosure is between 12-30 nucleotides (e.g., 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), or between 14-23 nucleotides (e.g., 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the sense strand is 15 nucleotides in length. In some embodiments, the sense strand is 16 nucleotides in length. In some embodiments, the sense strand is 17 nucleotides in length. In some embodiments, the sense strand is 18 nucleotides in length. In some embodiments, the sense strand is 19 nucleotides in length. In some embodiments, the sense strand is 20 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length. In some embodiments, the sense strand is 22 nucleotides in length. In some embodiments, the sense strand is 23 nucleotides in length. In some embodiments, the sense strand is 24 nucleotides in length. In some embodiments, the sense strand is 25 nucleotides in length. In some embodiments, the sense strand is 26 nucleotides in length. In some embodiments, the sense strand is 27 nucleotides in length. In some embodiments, the sense strand is 28 nucleotides in length. In some embodiments, the sense strand is 29 nucleotides in length. In some embodiments, the sense strand is 30 nucleotides in length.
[0171] 2' sugar modification The present disclosure may include ss-siRNA and ds-siRNA molecular compositions that include at least one (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or more) nucleoside with a 2' sugar modification. Possible 2'-modifications include all possible orientations of OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl can be substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. In some embodiments, the modification includes a 2'-O-methyl (2'-O-Me) modification. Other potential sugar substituents include C1-C10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacokinetic properties of an oligonucleotide, and other substituents with similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-CH2CH2OCH3, also known as 2'-O-(2-methoxyethyl) or 2'-MOE). In some embodiments, modifications include the group 2'-dimethylaminooxyethoxy, i.e., O(CH2)2ON(CH3)2, also known as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylamino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CHOCH2N(CH3). Other potential sugar substituents include, for example, aminopropoxy (-OCH2CH2CH2NH2), allyl (-CH2-CH=CH2), -O-allyl (-O-CH2-CH=CH2), and fluoro (F). The 2'-sugar substituent can be in the arabino (up) or ribo (down) position. In some embodiments, the 2'-arabino modification is 2'-F.Similar modifications may be made at other positions in the siRNA molecule, particularly the 3' position of the sugar in the 3' terminal nucleoside or 2'-5' linked oligonucleotides and the 5' position of the 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
[0172] Nucleobase Modifications The siRNA molecules of the present disclosure may also comprise nucleosides or other substitute or mimic monomer subunits that comprise nucleobases (often referred to in the art simply as "bases" or "heterocyclic base moieties").Nucleobases are other moieties that can be modified or substituted in a wide variety of ways, and such modified and / or substituted nucleobases can be in accordance with the present invention.As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases, also referred to herein as heterocyclic base moieties, include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine, and other alkynyl derivatives of pyrimidine bases. Derivatives include 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaguanine and 3-deazaguanine. Nucleobases may also include those in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone.Further nucleobases include those disclosed in US3,687,808, those disclosed in Kroschwitz, JI, ed. The Concise Encyclopedia of Polymer Science and Engineering, New York, John Wiley & Sons, 1990, pp. 858-859; those disclosed in Englisch et al., Angewandte Chemie, International Edition 30:613, 1991; and those disclosed in Sanghvi, YS, Chapter 16, Antisense Research and Applications, CRC Press, Gait, MJ ed., 1993, pp. 289-302. The siRNA molecules of the present disclosure can also contain polycyclic heterocyclic compounds instead of one or more heterocyclic base moieties. Many tricyclic heterocyclic compounds have been reported. These compounds are routinely used in antisense applications to increase the binding properties of modified strand to target strand.
[0173] Representative cytosine analogs that make three hydrogen bonds with guanosine in the second strand include 1,3-diazaphenoxazin-2-one (Kurchavov et al., Nucleosides and Nucleotides, 16:1837-46, 1997), 1,3-diazaphenothiazin-2-one (Lin et al. Am. Chem. Soc., 117:3873-4, 1995), and 6,7,8,9-tetrafluoro-1,3-diazaphenoxazin-2-one (Wang et al., Tetrahedron Lett., 39:8385-8, 1998). These base modifications incorporated into oligonucleotides have been shown to hybridize with complementary guanines, which in turn have been shown to hybridize with adenines through extended stacking interactions, improving the thermal stability of the helix (see also US10 / 155,920 and US10 / 013,295, both of which are incorporated herein by reference in their entireties). Further helix stabilizing properties have been observed when cytosine analogs / substitutes bear aminoethoxy moieties attached to a rigid 1,3-diazaphenoxazin-2-one scaffold (Lin et al., Am. Chem. Soc., 120:8531-2,1998).
[0174] Internucleoside bond modification Another variable in the design of the present invention is the internucleoside bond that constitutes the phosphate backbone of the siRNA molecule.Natural RNA phosphate backbone may be employed herein, but derivatives thereof may be used to improve the desired properties of the siRNA molecule.Of particular importance in this disclosure, but not limited to, is to protect part or the entire siRNA molecule from hydrolysis.One example of the modification that reduces the rate of hydrolysis is phosphorothioate.Any part or the entire backbone may contain phosphate substitution (e.g., phosphorothioate). For example, the internucleoside bond may be between 0 and 100% phosphorothioate, e.g., between 0 and 100%, 10 and 100%, 20 and 100%, 30 and 100%, 40 and 100%, 50 and 100%, 60 and 100%, 70 and 100%, 80 and 100%, 90 and 100%, 0 and 90%, 0 and 80%, 0 and 70%, 0 and 60%, 0 and 50%, 0 and 40%, 0 and 30%, 0 and 20%, 0 and 10%, 10 and 90%, 20 and 80%, 30 and 70%, 40% and 60%, 10 and 40%, 20 and 50%, 30 and 60%, 40 and 70%, 50 and 80%, or 60 and 90% phosphorothioate bond. Similarly, the internucleoside bond may be between 0 and 100% phosphodiester bonds, for example, between 0 and 100%, 10 and 100%, 20 and 100%, 30 and 100%, 40 and 100%, 50 and 100%, 60 and 100%, 70 and 100%, 80 and 100%, 90 and 100%, 0 and 90%, 0 and 80%, 0 and 70%, 0 and 60%, 0 and 50%, 0 and 40%, 0 and 30%, 0 and 20%, 0 and 10%, 10 and 90%, 20 and 80%, 30 and 70%, 40% and 60%, 10 and 40%, 20 and 50%, 30 and 60%, 40 and 70%, 50 and 80%, or 60 and 90% phosphodiester bonds.
[0175] Specific examples of some potential siRNA molecules useful in the present invention include oligonucleotides that contain modified, for example, non-naturally occurring internucleoside linkages.As defined herein, oligonucleotides with modified internucleoside linkages include internucleoside linkages that retain phosphorus atoms and internucleoside linkages that do not have phosphorus atoms.For the purposes of this specification and as sometimes referred to in the art, modified oligonucleotides that do not have phosphorus atoms in their internucleoside backbone can also be considered to be oligonucleosides.Preferred phosphorus-containing modified internucleoside linkages are phosphorothioate internucleoside linkages. In some embodiments, modified oligonucleotide backbones comprising a phosphorus atom therein include, for example, phosphorothioates, phosphodioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thinophosphoramidates, thinoalkyl phosphonates, thinoalkyl phosphotriesters, selenophosphates, boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs thereof, as well as those having inverted polarity where one or more internucleotide linkages are 3'-3', 5'-5', or 2'-2' linkages.Exemplary United States patents describing the preparation of phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; Same No. 5,321,131; Same No. 5,399,676; Same No. 5,405,939; Same No. 5,453,496; Same No. 5,455,233; Same No. 5,466,677; Same No. 5,476, No. 925; No. 5,519,126; No. 5,536,821; No. 5,541,316; No. 5,550,111; No. 5,563,253; No. 5,571,799; No. 5, No. 587,361; No. 5,625,050; No. 6,028,188; No. 6,124,445; No. 6,160,109; No. 6,169,170; No. 6,172,209 ; Same No. 6,239,265; Same No. 6,277,603; Same No. 6,326,199; Same No. 6,346,614; Same No. 6,444,423; Same No. 6,531,590; Same No. 6,534, Nos. 6,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Patent No. RE39464, the entire contents of each of which are incorporated herein by reference.
[0176] In some embodiments, modified oligonucleotide backbones that do not contain phosphorus atoms therein have backbones formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages. These include morpholino linkages (formed in part from the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; riboacetyl backbones; alkene-containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and other backbones with mixed N, O, S and CH2 moieties. Non-limiting examples of U.S. patents that teach the preparation of non-phosphorus scaffolds include, but are not limited to, U.S. Pat. Nos. 5,034,506, 5,166,315, 5,185,444, 5,214,134, 5,216,141, 5,235,033, 5,64,562, 5,264,564, 5,405,938, 5,434,257, 5,466,677, 5,470,967, 5,512,111, and 5,512,112. Nos. 5,489,677, 5,541,307, 5,561,225, 5,596,086, 5,602,240, 5,608,046, 5,610,289, 5,618,704, 5,623,070, 5,663,312, 5,633,360, 5,677,437, and 5,677,439, the entire contents of each of which are incorporated herein by reference.
[0177] Modification patterns of siRNA molecules The following section provides a set of exemplary scaffolds into which the siRNA molecules of the present disclosure can be incorporated.
[0178] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula I, where Formula I is in the 5'-3' direction: AB-(A') j -CP 2 -DP 1 -(C'-P 1 ) k -C' Formula I; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula CP 2 -DP 2 -DP 2 -DP 2 each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 4. In some embodiments, k is 4. In some embodiments, j is 4 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid sequence.
[0179] In some embodiments, the antisense strand comprises a structure represented by Formula A1, which in the 5'-3' direction is: ASBSAOBOBOBOAOBOAOBOA-OBOAOBOAOBSASASASBSA Formula A1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0180] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula II, which in the 5'-3' direction is: AB-(A') j -CP 2 -DP 1 -(CP 1 ) k -C' Formula II; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula CP 2 -DP 2 -DP 2 -DP 2 each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 4. In some embodiments, k is 4. In some embodiments, j is 4 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid sequence.
[0181] In some embodiments, the antisense strand comprises a structure represented by Formula A2, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAAOBOAOBSASASASASA Formula A2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0182] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula III, which in the 5'-3' direction is: E-(A') m -F Formula III; In the formula, E is the formula (CP 1 )2; F is represented by the formula (CP 2 )3-DP 1 -CP 1 -C, (CP 2 )3-DP 2 -CP 2 -C, (CP 2 )3-DP 1 -CP 1 -D, or (CP 2 )3-DP 2 -CP 2 -D; A', C, D, P 1 , and P 2 is as defined in Formula I; and m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 4. The sense strand is complementary (e.g., completely or partially complementary) to the antisense strand.
[0183] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S1, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBBSASA Formula S1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0184] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S2, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOA Formula S2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0185] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S3, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBSASB formula S3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0186] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S4, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOB Equation S4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0187] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula IV, where Formula IV is in the 5'-3' direction: A-(A') j -CP 2 -B-(CP 1 ) k -C' Formula IV; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula DP 1 -CP 1 -DP 1 each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 6. In some embodiments, k is 4. In some embodiments, j is 6 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid.
[0188] In some embodiments, the antisense strand comprises a structure represented by Formula A3, which, in the 5'-3' direction, is: ASBSAOBOAOBOAOBOAOBOA-OBOAOBOAOBSASASASA formula A3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0189] In some embodiments of the present disclosure, the siRNA of the present disclosure can have a sense strand represented by Formula V, where Formula V is, in the 5'-3' direction, the following: E-(A') m -CP 2 -F formula V; In the formula, E is the formula (CP 1 )2; F is represented by the formula DP 1 -CP 1 -C, D.P. 2 -CP 2 -C, D.P. 1 -CP 1 -D, or DP 2 -CP 2 -D; A', C, D, P 1 , and P 2 is as defined in formula IV; and m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 5. The sense strand is complementary (e.g., fully or partially complementary) to the antisense strand.
[0190] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S5, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASA Formula S5; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0191] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S6, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOA Formula S6; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage. In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S7, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASB Formula S7; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0192] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S8, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOB formula S8; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0193] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula VI, where Formula VI is in the 5'-3' direction: A.B. j -EB k -EFG l -DP 1 -C' Formula VI; where A is of the formula CP 1 -DP1 Each B is represented by the formula CP 2 each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; each E is represented by the formula DP 2 -CP 2 F is represented by the formula DP 1 -CP 1 Each G is represented by the formula CP 1 Each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and l is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 3. In some embodiments, k is 6. In some embodiments, l is 2. In some embodiments, j is 3, k is 6, and l is 2. The antisense strand is complementary (e.g., fully or partially complementary) to a target nucleic acid.
[0194] In some embodiments, the antisense strand comprises a structure represented by Formula A4, which, in the 5'-3' direction, is: ASBSAOAOAOBOAOAOAOAOA-OAOAOBOAOBSASASASBSA formula A4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0195] In some embodiments of the present disclosure, the siRNA may contain a sense strand that includes a region represented by Formula VII, which in the 5'-3' direction is: HBm -I n -A'-B o -HC Formula VII; where A' is a compound of the formula CP 2 -DP 2 Each H is represented by the formula (CP 1 )2; each I is represented by the formula (DP 2 ) are represented by B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); n is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and o is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 3. In some embodiments, n is 3. In some embodiments, o is 3. In some embodiments, m is 3, n is 3, and o is 3. The sense strand is complementary (e.g., fully or partially complementary) to the antisense strand.
[0196] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S9, which in the 5'-3' direction is: ASASAOAOAOBOBOBOAOBOA-OAOAOAASASA Formula S9; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
[0197] In some embodiments of the present disclosure, the siRNA may contain an antisense strand comprising a region represented by Formula VIII: Z-((AP-) n (BP-) m ) q ; Formula VIII wherein Z is a 5' phosphorus stabilizing moiety; each A is a 2'-O-methyl (2'-O-Me) ribonucleoside; each B is a 2'-fluoro-ribonucleoside; each P is independently an internucleoside linkage selected from a phosphodiester linkage and a phosphorothioate linkage; n is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5); m is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5); and q is an integer between 1 and 30 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30).
[0198] Methods for synthesizing siRNA The siRNA molecules of the present disclosure can be synthesized by standard methods known in the art, for example, by use of an automated DNA synthesizer such as those commercially available from Biosearch, Applied Biosystems, Inc., as discussed further below.
[0199] siRNA agent can be prepared by using liquid phase organic synthesis or solid phase organic synthesis or both.Organic synthesis has the advantage that it is easy to prepare the oligonucleotide that contains non-natural nucleotide or modified nucleotide.The siRNA molecule of the present disclosure can be prepared by using liquid phase organic synthesis or solid phase organic synthesis or both.
[0200] Furthermore, it is contemplated that any siRNA agent disclosed herein can be further optimized by systematically adding or removing linked nucleosides to generate longer or shorter sequences.Furthermore, such optimized sequences can be adjusted by introducing modified nucleosides and / or modified internucleoside linkages, as described herein or known in the art, including, for example, alternative nucleosides, alternative sugar moieties, and / or alternative internucleoside linkages, as known in the art and / or discussed herein, to further optimize the molecule (e.g., increase serum stability or circulating half-life, increase thermal stability, enhance transmembrane delivery, and / or target to specific locations or cell types).
[0201] 5' phosphorus stabilizing moiety To further protect the siRNA molecules of the present disclosure from degradation, a 5'-phosphorus stabilizing moiety can be employed. The 5'-phosphorus stabilizing moiety replaces the 5'-phosphate to prevent hydrolysis of the phosphate. Hydrolysis of the 5'-phosphate prevents binding to RISC, a necessary step of gene silencing. Any substitution of the phosphate that does not prevent binding to RISC is contemplated in the present disclosure. In some embodiments, the 5'-phosphate substitution is also stable to hydrolysis in vivo. Each strand of the siRNA molecule may independently and optionally employ any suitable 5'-phosphorus stabilizing moiety. [ka]
[0202] Some exemplary end caps are illustrated in Formulae IX-XVI. Nuc in Formulae IX-XVI represents a nucleobase or nucleobase derivative or substitute as described herein. X in Formulae IX-XVI represents a 2'-modification as described herein. Some embodiments employ hydroxy as in Formula IX, phosphate as in Formula X, vinyl phosphonate as in Formulae XI and XIV, 5'-methyl substituted phosphate as in Formulae XII, XIII, and XVI, methylene phosphonate as in Formula XV, or vinyl 5'-vinyl phosphonate as shown in Formula XI as the 5'-phosphorus stabilizing moiety.
[0203] hydrophobic part The present disclosure further provides siRNA molecules with one or more hydrophobic moieties attached.Hydrophobic moieties can be covalently attached to the 5'-end or 3'-end of the siRNA molecules of the present disclosure.Non-limiting examples of the hydrophobic moieties suitable for use with the siRNA molecules of the present disclosure can include cholesterol, vitamin D, tocopherol, phosphatidylcholine (PC), docohexaenoic acid, docosanoic acid, PC-docosanoic acid, eicosapentaenoic acid, lithocholic acid, or any combination of the aforementioned hydrophobic moieties and PC.
[0204] siRNA branching The siRNA molecules of the present disclosure may be branched. For example, the siRNA molecules of the present disclosure may have one of several branching patterns as described herein.
[0205] According to the present disclosure, the siRNA molecule disclosed herein may be a branched siRNA molecule. The siRNA molecule may be unbranched or bi-, tri- or tetra-branched, connected via a linker. Each main branch may be further branched to allow 2, 3, 4, 5, 6, 7 or 8 separate RNA single or double strands. The branching points on the linker may originate from the same atom or may originate from separate atoms along the linker. Some exemplary embodiments are listed in Table 2. [Table 2]
[0206] In some embodiments, the siRNA molecule is a branched siRNA molecule. In some embodiments, the branched siRNA molecule is biantennary, triantennary, or tetraantennary. In some embodiments, the biantennary siRNA molecule is represented by any one of formulas XVII-XIX, where each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety (e.g., phosphoramidite, tosylated solketal, 1,3-diaminopropanol, pentaerythritol, or any one of the branch point moieties described in US10,478,503).
[0207] In some embodiments, the three-branched siRNA molecule is represented by any one of formulas XX-XXIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
[0208] In some embodiments, the four-branched siRNA molecule is represented by any one of Formulas XXIV-XXVIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
[0209] Linker The multiple strands of the siRNA described herein may be covalently linked by a linker. This branching effect, among other things, improves cell permeability, allowing better access to cells (e.g., neurons or glial cells) in the CNS. Any linker moiety that is not incompatible with the siRNA of the present invention may be employed. Linkers include ethylene glycol chains of 2-10 subunits (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 subunits), alkyl chains, carbohydrate chains, block copolymers, peptides, RNA, DNA, and others. In some embodiments, the carbon or oxygen atoms of the linker are optionally replaced with nitrogen atoms, have hydroxyl substituents, or have oxo substituents. In some embodiments, the linker is a polyethylene glycol (PEG) linker. PEG linkers suitable for use in the disclosed compositions and methods include linear or non-linear PEG linkers. Examples of non-linear PEG linkers include branched PEG, linear forked PEG, or branched forked PEG.
[0210] PEG linkers of various weights may be used in the disclosed compositions and methods. For example, the PEG linker may have a weight between 5 and 500 daltons. In some embodiments, a PEG linker having a weight between 500 and 1,000 daltons may be used. In some embodiments, a PEG linker having a weight between 1,000 and 10,000 daltons may be used. In some embodiments, a PEG linker having a weight between 200 and 20,000 daltons may be used. In some embodiments, the linker is covalently attached to the sense strand of the siRNA. In some embodiments, the linker is covalently attached to the antisense strand of the siRNA. In some embodiments, the PEG linker is a triethylene glycol (TrEG) linker. In some embodiments, the PEG linker is a tetraethylene glycol (TEG) linker.
[0211] In some embodiments, the linker is an alkyl chain linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is an RNA linker. In some embodiments, the linker is a DNA linker.
[0212] The linker may covalently link two, three, four, or five unique siRNA strands. The linker may be covalently linked to any portion of the siRNA oligomer. In some embodiments, the linker is attached to the 3' end of the nucleoside of each siRNA strand. In some embodiments, the linker is attached to the 5' end of the nucleoside of each siRNA strand. In some embodiments, the linker is attached to the nucleoside of the siRNA strand (e.g., the sense strand or the antisense strand) via a covalent bond forming moiety. In some embodiments, the covalent bond forming moiety is selected from the group consisting of alkyl, ester, amide, carbonate, carbamate, triazole, urea, formacetal, phosphonate, phosphate, and phosphate derivatives (e.g., phosphorothioate, phosphoramidate, etc.).
[0213] In some embodiments, the linker has the structure of formula L1. [ka]
[0214] In some embodiments, the linker has the structure of formula L2: [ka]
[0215] In some embodiments, the linker has the structure of formula L3. [ka]
[0216] In some embodiments, the linker has the structure of formula L4. [ka]
[0217] In some embodiments, the linker has the structure of formula L5. [ka]
[0218] In some embodiments, the linker has the structure of formula L6. [ka]
[0219] In some embodiments, the linker has the structure of formula L7, as shown below: [ka]
[0220] In some embodiments, the linker has the structure of formula L8. [ka]
[0221] In some embodiments, the linker has the structure of formula L9. [ka]
[0222] In some embodiments, the selection of a linker for use in one or more of the branched siRNA molecules disclosed herein may be based on the hydrophobicity of the linker, for example, to achieve a desired hydrophobicity for one or more of the branched siRNA molecules of the present disclosure.For example, a linker containing an alkyl chain may be used to increase the hydrophobicity of the branched siRNA molecule compared to a branched siRNA molecule having a less hydrophobic or hydrophilic linker.
[0223] The siRNA agents disclosed herein can be synthesized and / or modified by methods well established in the art, such as those described in Beaucage, SL et al. (eds.), Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc., New York, NY, 2000, which is incorporated herein by reference.
[0224] Treatment method The KCNT1-targeted siRNA molecule of the present disclosure can be delivered to a subject, for example, as an anticonvulsant, thereby reducing the duration or frequency of epilepsy events and / or alleviating epilepsy-related phenotypes (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, or cardiac arrhythmia).Furthermore, the siRNA molecule of the present disclosure can be delivered to a subject having a variant of the KCNT1 gene, and the siRNA-mediated gene silencing of the KCNT1 variant gene reduces the expression level of the KCNT1 transcript, thereby reducing the duration or frequency of epilepsy events and / or alleviating epilepsy-related phenotypes (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, or cardiac arrhythmia).
[0225] Many pathological KCNT1 variants that cause epilepsy cause enhanced function, which is manifested as an increase in potassium ion current through the KCNT1 channel. Therefore, pharmacologically reducing KCNT1 expression levels should provide therapeutic benefits. The present disclosure provides a method of treating a subject by KCNT1 gene silencing with one or more siRNA molecules described herein. Gene silencing can be performed in a subject to silence wild-type KCNT1 transcripts, mutant KCNT1 transcripts, splice isoforms of KCNT1 transcripts, and / or their overexpressed KCNT1 transcripts compared to healthy subjects. The method can include delivering the siRNA molecule of the present disclosure or a pharmaceutical composition containing it to the CNS of a subject (e.g., a human) by any suitable administration route (e.g., intracerebroventricular, intrathecal injection, or intracisternal injection by catheter insertion). The active compound can be administered at any suitable dose. The actual dosage of the composition of the present disclosure administered to a patient can be determined by physical and physiological factors such as body weight, severity of the condition, prior or concurrent therapeutic interventions, idiopathic diseases of the patient, and route of administration. Depending on the dosage and route of administration, the preferred dosage and / or the number of administrations of an effective amount can vary depending on the subject's response. The practitioner responsible for administration will in any event determine the concentration of the active ingredient(s) in the composition and the appropriate dose(s) for the individual subject. Administration can be any suitable number of times per day for the period required. The subject may be an adult or pediatric human, with or without co-morbidities.
[0226] Selecting a target The subject that can be treated with the siRNA molecules disclosed herein is, for example, a subject that needs treatment for epilepsy, epilepsy-related phenotype (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, or cardiac arrhythmia), and / or other medical risk(s) associated with gain-of-function mutations in the KCNT1 gene.Furthermore, the subject that needs treatment may be characterized as having a particular epilepsy syndrome. For example, a subject may be diagnosed with frontal lobe epilepsy, occipital lobe epilepsy, mesial temporal lobe epilepsy, parietal lobe epilepsy, benign myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, Lennox-Gastaut syndrome, West syndrome, sleep-related hyperkinetic epilepsy, progressive myoclonic epilepsy, febrile seizures, epilepsy with persistent spike-and-wave during slow-wave sleep, Landau-Kleffner syndrome, Rasmussen syndrome, epilepsy due to inborn errors of metabolism, infantile epilepsy with moving focal seizures, autosomal dominant nocturnal frontal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and / or multifocal epilepsy. The subject that can be treated with the siRNA molecules disclosed herein may include, for example, humans, monkeys, rats, mice, pigs, and other mammals that contain at least one homologous copy of the KCNT1 gene. The subject may be an adult or pediatric human, with or without comorbidities.
[0227] Pharmaceutical Compositions The siRNA molecule of the present disclosure can be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo.Therefore, the present disclosure provides pharmaceutical compositions that contain the siRNA molecule of the present disclosure mixed with suitable diluent, carrier or excipient.The siRNA molecule can be directly administered to the CNS or affected tissue of subjects, for example, by intraventricular injection, intrastriatal injection, intrathecal injection, intracisternal injection by catheter insertion, intraparenchymal injection, intravenous injection, subcutaneous injection or intramuscular injection.
[0228] Procedures and ingredients for selecting and preparing suitable formulations are described, for example, in Remington, JP The Science and Practice of Pharmacy, Easton, PA. Mack Publishers, 2012, 22 nd ed. and the United States Pharmacopeial Convention, The National Formulary, United States Pharmacopeial, 2015, USP 38 NF 33).
[0229] Under normal storage and use conditions, the pharmaceutical compositions may contain preservatives, for example, to prevent the growth of microorganisms. The pharmaceutical compositions may include sterile aqueous solutions, sterile dispersions, or powders, for example, for the extemporaneous preparation of sterile solutions or dispersions. In all cases, the forms can be sterilized using techniques known in the art and can be fluidized to the extent that they can be easily administered to the subject in need of treatment.
[0230] Pharmaceutical compositions may be administered to a subject, e.g., a human subject, alone or in combination with pharma- ceutically acceptable carriers, as provided herein, the proportions of which may be determined by the solubility and / or chemical properties of the compound, the chosen route of administration, and standard pharmaceutical practice.
[0231] Dosing regimen A physician of ordinary skill in the art can easily determine the effective amount of siRNA molecules to administer to a mammalian subject (e.g., human) in need thereof. For example, a physician can begin to prescribe a dose of one of the siRNA molecules of the present disclosure at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician can begin a treatment regimen by administering one of the siRNA molecules of the present disclosure at a high dose, and then administer progressively lower doses until the minimum dosage at which a therapeutic effect (e.g., reduction in expression of a target gene sequence) is reached. In general, a suitable daily dose of one of the siRNA molecules of the present disclosure is the amount of the lowest dose of the siRNA molecule effective to produce a therapeutic effect. The ss- or ds-siRNA molecules of the present disclosure can be administered by injection, for example, intrathecal, intracerebroventricular, intracisternal injection by catheter insertion, intraparenchymal, intravenous, subcutaneous, or intramuscular injection. The daily dosage of the therapeutic composition of the siRNA molecule of the present disclosure may be administered as a single dose, or as two, three, four, five, six or more doses administered separately at appropriate intervals throughout the day, week, month or year, optionally in unit dosage form.The siRNA molecule of the present disclosure can be administered alone, but can also be administered in pharmaceutical formulations in combination with excipients, carriers and optionally additional therapeutic agents.
[0232] Route of administration The disclosed methods contemplate any route of administration tolerated by the therapeutic composition. Some embodiments of the methods include intrathecal, intraventricular, or intracisternal injection via catheter insertion.
[0233] Intrathecal injection is a direct injection into the spinal column or subarachnoid space. By injecting directly into the CSF of the spinal column, the siRNA molecules of the present disclosure have direct access to cells (e.g., neurons and glial cells) in the spinal column and have a route to bypass the blood-brain barrier and access cells in the brain.
[0234] Intracerebroventricular (ICV) injection is a method of injection directly into the CSF in the ventricles of the brain. Like intrathecal injection, ICV is an injection method that bypasses the blood-brain barrier. The use of ICV offers the advantage of accessing cells in the brain and spinal column without the risk of the therapeutic agent being degraded in the blood.
[0235] Intrastriatal injection is a direct injection into the striatum (or corpus striatum), a subcortical basal ganglia region of the brain. Injection into the striatum bypasses the blood-brain barrier, avoiding the pharmacokinetic challenges of injection into the bloodstream, and allows direct access to brain cells.
[0236] Intraparenchymal administration is direct injection into the parenchyma (e.g., brain parenchyma). Injection into the brain parenchyma allows for direct injection into the brain region affected by the disease or disorder, bypassing the blood-brain barrier.
[0237] Intracisternal injection by catheterization is a direct injection into the cisterna magna, an area of the brain located between the cerebellum and the dorsal aspect of the medulla oblongata. Injection into the cisterna magna provides more direct delivery to cells in the cerebellum, brainstem, and spinal cord.
[0238] In some embodiments of the methods described herein, the therapeutic composition can be delivered to the subject by systemic administration, for example, intravenous, intramuscular, or subcutaneous administration.
[0239] Intravenous (IV) injection is a method of injection directly into the bloodstream of a subject. IV administration may be in the form of a bolus dose, by continuous infusion, or any other method permitted by the therapeutic composition.
[0240] An intramuscular (IM) injection is an injection into a muscle of the subject, such as the deltoid or gluteal muscle. IM may allow for rapid absorption of the therapeutic composition.
[0241] Subcutaneous injections are injections into the subcutaneous tissue. Absorption of compositions delivered subcutaneously may be slower than IV or IM injections, which may be beneficial for compositions that require continuous absorption. EXAMPLES
[0242] The following examples are presented to provide one of ordinary skill in the art with an illustration of how the compositions and methods described herein can be used, made, and evaluated, and are intended to be purely illustrative of the disclosure and are not intended to limit the scope of what the inventors regard as their disclosure.
[0243] Example 1. Knockdown of KCNT1 by siRNA molecules of the present disclosure All screening assays were performed by measuring mRNA levels of KCNT1 and a housekeeping gene (ATP5B) in cell culture lysates by reverse transcription quantitative polymerase chain reaction (RT-qPCR) using standard reagents and Applied Biosystems TaqMan assays. For passive screening (Table 3 below), SK-N-BE(2) cells were cultured in the presence of KCNT1 siRNA at a concentration of either 2 μM or 0.5 μM. For active screening (Table 4 below), HEK cells stably expressing KCNT1 (HEK-KCNT1) were actively transfected with KCNT1 siRNA at a concentration of either 20 nM or 0.2 nM. For compound potency analysis, HEK-KCNT1 cells were actively transfected with KCNT1 siRNA at concentrations ranging from 10 fM to 100 nM and IC50 was calculated. For all assays, cells were dosed with siRNA for 72 hours before lysis and downstream analysis. Results are shown as the percentage of remaining KCNT1 mRNA compared to untreated control cells in the same assay (in % KCNT1 mRNA), STDEV=standard deviation, ND=not determined. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5]
[0244] Example 2. IC50 Determination of siRNA Molecules of the Present Disclosure For compound potency analysis, HEK-KCNT1 cells were actively transfected with KCNT1 siRNA at concentrations ranging from 10 fM to 100 nM and IC50 was calculated. Cells were dosed with siRNA for 72 hours prior to lysis and downstream analysis. Expression was determined using the methods described above. An siRNA molecule with an antisense strand of SEQ ID NO: 19 and a sense strand of SEQ ID NO: 237 was tested in this assay. IC50 was determined to be 0.0415. The IC50 curve is shown in Figure 1.
[0245] Example 3. Generation of KCNT1-targeting siRNA molecules The siRNA molecules of the present disclosure can be synthesized by standard methods known in the art, for example, by use of an automated DNA synthesizer such as those commercially available from Biosearch, Applied Biosystems, Inc., as discussed further below.
[0246] siRNA agents can be prepared using liquid phase organic synthesis or solid phase organic synthesis, or both. Organic synthesis has the advantage that oligonucleotides containing non-natural or modified nucleotides can be easily prepared. Specific examples of siRNA molecules are shown in Table 1 above, with the nucleotide sequences of sense and antisense strands, and the sodium-activated potassium channel subfamily T member 1 (KCNT1) mRNA target sequence. Those skilled in the art will understand that antisense (AS) strands can be annealed to corresponding sense (S) strands to generate ds-siRNA molecules. Alternatively, those skilled in the art can use only antisense strands to induce ss-siRNA molecules.
[0247] Example 4. Optimization of KCNT1-targeting siRNA molecules For any small interfering RNA (siRNA) agent disclosed herein, it is contemplated that modifications to siRNA can further optimize the efficacy or biophysical properties of the molecule (e.g., increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, and / or targeting to a specific location or cell type). Such optimization can be achieved for any siRNA agent disclosed herein by systematically adding or removing linked nucleosides to generate longer or shorter sequences. Further optimization of siRNA can include, for example, the incorporation of one or more alternative nucleosides, alternative 2' sugar moieties, and / or alternative internucleoside linkages. Furthermore, such optimized siRNA molecules can include the introduction of hydrophobic and / or stabilizing moieties at the 5' and / or 3' ends.
[0248] Optimizing siRNA with alternative nucleosides Optimization of the siRNA molecules of the present disclosure may include one or more of the following nucleoside modifications: 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine, and other alkynyl derivatives of pyrimidine bases. , 6-azo-uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, and / or 7-deazaguanine and 3-deazaguanine. siRNA molecules may also include nucleobases in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and / or 2-pyridone. Further optimization of the siRNA molecules of the present disclosure may include nucleobases disclosed in US 3,687,808; Kroschwitz, JI, ed. The Concise Encyclopedia of Polymer Science and Engineering, New York, John Wiley & Sons, 1990, pp. 858-859; Englisch et al., Angewandte Chemie, International Edition 30:613, 1991; and Sanghvi, YS, Chapter 16, Antisense Research and Applications, CRC Press, Gait, MJ ed., 1993, pp. 289-302.
[0249] Optimization of siRNAs by alternative sugar modifications Optimization of the siRNA molecules of the present disclosure may include one or more of the following 2' sugar modifications: 2'-O-methyl (2'-O-Me), 2'-methoxyethoxy (also known as 2'-O-CH2CHOCH3, 2'-O-(2-methoxyethyl) or 2'-MOE), 2'-dimethylaminooxyethoxy, i.e., O(CH2)2ON(CH3)2 group, also known as 2'-DMAOE, and / or 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylamino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CHOCH2N(CH3)2. Other possible 2' modifications that can optimize the siRNA molecules of the present disclosure include all possible orientations of OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl include all possible orientations of substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. Other potential sugar substituents include, for example, aminopropoxy (-OCH2CH2CH2NH2), allyl (-CH2-CH=CH2), -O-allyl (-O-CH2-CH=CH2), and fluoro (F). The 2'-sugar substituent can be in the arabino (up) or ribo (down) position. In some embodiments, the 2'-arabino modification is 2'-F. Similar modifications may be made at other positions in the siRNA molecule, particularly the 3' position of the sugar in the 3' terminal nucleoside or 2'-5' linked oligonucleotides and the 5' position of the 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
[0250] Optimization of siRNAs with alternative internucleoside linkages Optimization of the siRNA molecules of the present disclosure may include one or more of the following internucleoside modifications: phosphorothioates, phosphodioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thinophosphoramidates, thinoalkyl phosphonates, thinoalkyl phosphotriesters, selenophosphates, boranophosphates with normal 3'-5' linkages, 2'-5' linked analogs of these, as well as those with inverted polarity where one or more internucleotide linkages are 3'-3', 5'-5', or 2'-2' linkages.
[0251] Optimization of siRNA using hydrophobic moieties The optimization of the siRNA molecule of the present disclosure may include covalently linked hydrophobic moiety at 5'-end or 3'-end.The non-limiting examples of the hydrophobic moiety suitable for use with the siRNA molecule of the present disclosure may include cholesterol, vitamin D, tocopherol, phosphatidylcholine (PC), docohexaenoic acid, docosanoic acid, PC-docosanoic acid, eicosapentaenoic acid, lithocholic acid, or any combination of the above hydrophobic moiety and PC.
[0252] Optimization of siRNA using stabilizing molecules The optimization of the siRNA molecules of the present disclosure may include a 5'-phosphorus stabilizing moiety that protects the siRNA molecules from degradation. The 5'-phosphorus stabilizing moiety replaces the 5'-phosphate to prevent hydrolysis of the phosphate. Hydrolysis of the 5'-phosphate prevents binding to RISC, which is a necessary step of gene silencing. Any substitution of the phosphate that does not prevent binding to RISC is contemplated in the present disclosure. In some embodiments, the substitution of the 5'-phosphate is also stable to hydrolysis in vivo. Each siRNA strand may independently and optionally employ any suitable 5'-phosphorus stabilizing moiety. Non-limiting examples of 5' stabilizing moieties suitable for use with the siRNA molecules of the present disclosure include those shown in formulas IX to XVI above.
[0253] Optimization of siRNA using branched siRNA The optimization of the siRNA molecule of the present disclosure may include the incorporation of branching patterns, such as bi-branched, tri-branched, or tetra-branched siRNAs connected via linker.Each main branch may be further branched to allow 2, 3, 4, 5, 6, 7, or 8 separate RNA single strands or double strands.The branching points on the linker may originate from the same atom, or may originate from separate atoms along the linker.Some exemplary embodiments are listed in Table 2 above.
[0254] The siRNA compositions of the present disclosure can be optimized to be in the form of a biantennary siRNA molecule represented by any one of formulas XVII-XIX, a triantennary siRNA molecule represented by any one of formulas XX-XXIII, and / or a tetraantennary siRNA molecule represented by any one of formulas XXIV-XXVIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety (e.g., a phosphoramidite, a tosylated solketal, 1,3-diaminopropanol, pentaerythritol, or any one of the branch point moieties described in US 10,478,503).
[0255] Example 5. Preparation and administration of KCNT1-targeting siRNA molecules The siRNA molecule of the present disclosure can be formulated into a pharmaceutical composition for administration to a subject in a biologically compatible form suitable for administration in vivo.For example, the siRNA molecule of the present disclosure can be administered with a suitable diluent, carrier, or excipient, and can further include a preservative, for example, to prevent microbial growth.The procedure and ingredients for selecting and preparing a suitable formulation can be found, for example, in Remington, JP The Science and Practice of Pharmacy, Easton, PA. Mack Publishers, 2012, 22 nd ed. and the National Formulary, United States Pharmacopeial, 2015, USP 38 NF 33).
[0256] The method of the present disclosure contemplates the administration route to the CNS of the subject that is tolerated by the siRNA composition of the present disclosure.Non-limiting examples of siRNA injection to the CNS include intrathecal, intraventricular, or intracisternal injection by catheter insertion.A doctor of ordinary skill in the art can easily determine effective administration route.
[0257] Example 6. Methods for treating epilepsy using KCNT1-targeting siRNA molecules A subject in need of treatment for epilepsy and / or epilepsy-related phenotypes (e.g., seizures, perioral cyanosis, flushing, apnea, hypertonia, pulmonary hemorrhage, or cardiac arrhythmia) is treated with a dosage of the siRNA molecule or siRNA composition of the present disclosure, formulated as a salt, at a frequency determined by the physician. A physician of ordinary skill in the art can easily determine an effective amount of the siRNA molecule to administer to a mammalian subject (e.g., a human) in need thereof. For example, a physician can begin prescribing a dose of one of the siRNA molecules of the present disclosure at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician can begin a treatment regimen by administering one of the siRNA molecules of the present disclosure at a high dose, and then administer progressively lower doses until a minimum dose that results in a therapeutic effect (e.g., a reduction in the expression of KCNT1 mRNA or a suitable biomarker) is achieved. In general, a suitable daily dose of one of the siRNA molecules of the present disclosure is the amount of the minimum dose that is effective to produce a therapeutic effect. The ss-siRNA molecule or ds-siRNA molecule of the present disclosure can be administered by injection, for example, intrathecal, intracerebroventricular, or intracisternal injection by catheter insertion.The daily dose of the therapeutic composition of one of the siRNA molecules of the present disclosure can be administered as a single dose, or as two, three, four, five, six or more doses administered separately at appropriate intervals throughout the day, week, month, or year, optionally in unit dosage form.Any of the siRNA molecules of the present disclosure can be administered alone, but can also be administered in pharmaceutical formulations in combination with excipients, carriers, and optionally additional therapeutic agents.The dosage and frequency are determined based on the height, weight, age, sex, and other disorders of the subject.
[0258] The siRNA molecule of the present disclosure is selected by a physician considering its compatibility with a subject.Can select single-stranded or double-stranded siRNA molecules (e.g., unbranched siRNA, bibranched siRNA, tri-branched siRNA, tetra-branched siRNA).Selected siRNA molecule can have antisense strand and sense strand with optimal sequence and RNA modification for patient (e.g., natural and non-natural internucleoside bond, modified sugar, 5' phosphorus stabilizing portion, hydrophobic portion, and / or branched structure).
[0259] The siRNA molecules are delivered by the route best suited to the patient and condition (e.g., intrathecal, intracerebroventricular, or by intracisternal injection via catheterization) at a rate that can be tolerated by the patient until the subject reaches the maximum tolerated dose or until symptoms are sufficiently alleviated.
[0260] Other embodiments All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0261] While the invention has been described in relation to specific embodiments, it will be understood that the invention is capable of further modifications, and this application is generally intended to cover any variations, uses, or adaptations of the invention in accordance with the principles of the invention, including departures therefrom which come within known or customary practice in the art to which this invention pertains and which may be applied to the essential features hereinbefore described, and which fall within the scope of the appended claims.
[0262] Other embodiments are within the scope of the claims.
Claims
1. A small interfering RNA (siRNA) molecule comprising an antisense strand and a sense strand having complementarity to the antisense strand, wherein the antisense strand has sufficient complementarity to hybridize to a region within a sodium-activated potassium channel subfamily T member 1 (KCNT1) mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
2. The siRNA molecule of claim 1, wherein the antisense strand has at least 70% complementarity to a region of 19, 20, 21, or more consecutive nucleobases in the KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224, and optionally, the antisense strand has at least 70% complementarity to the KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
3. The siRNA molecule of claim 2, wherein the antisense strand has at least 75% complementarity to the region in the KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224, and optionally the antisense strand has at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementarity to the region in the KCNT1 mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
4. The siRNA molecule of any one of claims 1 to 3, wherein the antisense strand comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
5. The siRNA molecule of claim 4, wherein the antisense strand comprises 10 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
6. The siRNA molecule of claim 5, wherein the antisense strand comprises 12 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
7. The siRNA molecule of claim 6, wherein the antisense strand comprises 15 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
8. The siRNA molecule of claim 7, wherein the antisense strand comprises 18 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
9. The siRNA molecule of claim 8, wherein the antisense strand comprises 18 to 25 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
10. The siRNA molecule according to any one of claims 1 to 9, wherein the antisense strand comprises 18 to 21 consecutive nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437 to 654 and 1035 to 1224.
11. The siRNA molecule of claim 9, wherein the antisense strand comprises 21 consecutive nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
12. The siRNA molecule of any one of claims 1 to 11, wherein the antisense strand contains 9 or fewer nucleotide mismatches to the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224, and optionally, the antisense strand contains 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or only 1 mismatch to the region of the KCNT1 RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 437-654 and 1035-1224.
13. The siRNA molecule of any one of claims 1 to 12, wherein the antisense strand has a nucleic acid sequence that is at least 85% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1 to 218 and 655 to 844.
14. The siRNA molecule of claim 13, wherein the antisense strand has a nucleic acid sequence that is at least 90% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-218 and 655-844.
15. The siRNA molecule of claim 14, wherein the antisense strand has a nucleic acid sequence that is at least 95% identical to a nucleic acid sequence of SEQ ID NOs: 1-218 and 655-844, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to a nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844.
16. The siRNA molecule of claim 15, wherein the antisense strand has a nucleic acid sequence of any one of SEQ ID NOs: 1-218 and 655-844.
17. The siRNA molecule of any one of claims 1 to 16, wherein the sense strand has a nucleic acid sequence that is at least 85% identical to any one of the nucleic acid sequences of SEQ ID NOs: 219-436 and 845-1034.
18. The siRNA molecule of claim 17, wherein the sense strand has a nucleic acid sequence that is at least 90% identical to any one of the nucleic acid sequences of SEQ ID NOs: 219-436 and 845-1034.
19. 19. The siRNA molecule of claim 18, wherein the sense strand has a nucleic acid sequence that is at least 95% identical to a nucleic acid sequence of SEQ ID NOs: 219-436 and 845-1034, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to a nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034.
20. The siRNA molecule of claim 19, wherein the sense strand has a nucleic acid sequence of any one of SEQ ID NOs: 219-436 and 845-1034.
21. 21. The siRNA molecule of any one of claims 1 to 20, wherein the antisense strand has a structure represented by formula I, which in the 5'-3' direction is: A-B-(A’) j -C-P 2 -D-P 1 -(C’-P 1 ) k -C’ Formula I; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula C-P 2 -D-P 2 -D-P 2 -D-P 2 It is represented by: each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule, wherein k is an integer from 1 to 7.
22. The antisense strand has a structure represented by formula A1, which in the 5'-3' direction is: A-S-B-SA Formula A1; 22. The siRNA molecule of claim 21, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
23. 21. The siRNA molecule of any one of claims 1 to 20, wherein the antisense strand has a structure represented by Formula II, which in the 5'-3' direction is: A-B-(A’) j -C-P 2 -D-P 1 -(C-P 1 ) k -C’ Formula II; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula C-P 2 -D-P 2 -D-P 2 -D-P 2 It is represented by: each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule, wherein k is an integer from 1 to 7.
24. The antisense strand has a structure represented by formula A2, which in the 5'-3' direction is: A-S-B-SA Formula A2; 24. The siRNA molecule of claim 23, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
25. the sense strand has a structure represented by Formula III, which in the 5'-3' direction is: E-(A') m -F Formula III; In the formula, E is a compound represented by the formula (C-P 1 ) 2 It is represented by: F is represented by the formula (C-P 2 ), 3 -D-P 1 -C-P 1 -C, (C-P 2 ), 3 -D-P 2 -C-P 2 -C, (C-P 2 ), 3 -D-P 1 -C-P 1 -D, or (C-P 2 ), 3 -D-P 2 -C-P 2 -D; A', C, D, P 1 , and P 2 is as defined in formula II; The siRNA molecule of any one of claims 1 to 24, wherein m is an integer from 1 to 7.
26. The sense strand has a structure represented by formula S1, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-B-S-A-S-A Formula S1; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
27. The sense strand has a structure represented by formula S2, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-BO-O-A-O-A Formula S2; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
28. The sense strand has a structure represented by formula S3, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-B-S-A-S-B Formula S3; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
29. The sense strand has a structure represented by formula S4, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-BO-O-A-O-B Formula S4; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
30. the antisense strand has a structure represented by Formula IV, which in the 5'-3' direction is: A-(A’) j -C-P 2 -B-(C-P 1 ) k -C’ Formula IV; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula D-P 1 -C-P 1 -D-P 1 It is represented by: each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 20 and 25 to 29, wherein k is an integer from 1 to 7.
31. The antisense strand has a structure represented by formula A3, which in the 5'-3' direction is: A-S-B-S-A-O-B-O-A-O-B-O-A-O-BO-A-O-B-O-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-B-S-A-S-A Formula A3; 31. The siRNA molecule of claim 30, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
32. The sense strand comprises a structure represented by formula V, which in the 5'-3' direction is: E-(A’) m -C-P 2 -F Formula V; In the formula, E is a compound represented by the formula (C-P 1 ) 2 It is represented by: F is represented by the formula D - P 1 -C - P 1 -C, D - P 2 -C - P 2 -C, D - P 1 -C - P 1 -D, or D - P 2 -C - P 2 -D; A', C, D, P 1 , and P 2 is as defined in formula IV; The siRNA molecule of any one of claims 1 to 24, 30, and 31, wherein m is an integer from 1 to 7.
33. The sense strand has a structure represented by formula S5, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-A Formula S5; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
34. The sense strand has a structure represented by formula S6, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-BO-O-A-O-B-O-A-O-A Formula S6; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
35. The sense strand has a structure represented by formula S7, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-B Formula S7; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
36. The sense strand has a structure represented by formula S8, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-O-A-O-B Formula S8; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
37. the antisense strand has a structure represented by formula VI, which in the 5'-3' direction is: A-B j -E-B k -E-F-G l -D-P 1 -C’ Formula VI; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each B is of the formula C-P 2 It is represented by: each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each E is of the formula D-P 2 -C-P 2 It is represented by: F is the formula D-P 1 -C-P 1 It is represented by: Each G is of the formula C-P 1 It is represented by: Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; k is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 20, 25 to 29, and 32 to 36, wherein l is an integer from 1 to 7.
38. The antisense strand has a structure represented by formula A4, which in the 5'-3' direction is: A-S-B-S-A-O-A-O-A-O-BO-A-O-A-O-A-O-A-O-A-O-A-O-A-O-B-O-A-O-B-S-A-S-A-S-A-S-B-S-A Formula A4; 38. The siRNA molecule of claim 37, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
39. the sense strand comprises a structure represented by formula VII, which in the 5'-3' direction is: H-B m -I n -A’-B o -H-C Formula VII; In the formula, A′ is a compound of the formula C−P 2 -D-P 2 It is represented by: Each H is represented by the formula (C-P 1 ) 2 It is represented by: Each I is independently a group represented by the formula (D−P 2 ) represented by; B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7; n is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 24, 30, 31, 37, and 38, wherein o is an integer from 1 to 7.
40. The sense strand has a structure represented by formula S9, which in the 5'-3' direction is: A-S-A-S-A-O-A-O-A-O-B-O-BO-O-BO-A-O-BO-O-A-O-A-O-A-O-A-S-A-S-A Formula S9; 40. The siRNA molecule of claim 39, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.
41. The siRNA molecule of any one of claims 1 to 40, wherein the antisense strand further comprises a 5' phosphorus stabilizing moiety at the 5' end of the antisense strand.
42. The siRNA molecule of any one of claims 1 to 41, wherein the sense strand further comprises a 5' phosphorus stabilizing moiety at the 5' end of the sense strand.
43. each 5' phosphorus stabilizing moiety is independently represented by any one of formulas IX-XVI: 【Chemistry 1】 43. The siRNA molecule of claim 41 or 42, wherein Nuc represents a nucleobase selected from the group consisting of adenine, uracil, guanine, thymine, and cytosine, and R represents optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, phenyl, benzyl, or hydrogen.
44. The siRNA molecule of claim 43, wherein the nucleobase is adenine, uracil, guanine, thymine, or cytosine.
45. The siRNA molecule of any one of claims 41 to 44, wherein the 5' phosphorus stabilizing moiety is an (E)-vinyl phosphonate of formula XI.
46. The siRNA molecule of any one of claims 1 to 45, further comprising a hydrophobic moiety at the 5'-end or 3'-end of the siRNA molecule.
47. 47. The siRNA molecule of claim 46, wherein the hydrophobic moiety is selected from the group consisting of cholesterol, vitamin D, or tocopherol.
48. The siRNA molecule of any one of claims 1 to 47, wherein the sense strand is between 10 and 30 nucleotides in length.
49. The siRNA molecule of claim 48, wherein the sense strand is between 10 and 25 nucleotides in length.
50. The siRNA molecule of claim 49, wherein the sense strand is between 12 and 25 nucleotides in length.
51. The siRNA molecule of claim 50, wherein the sense strand is between 12 and 20 nucleotides in length.
52. The siRNA molecule of claim 51, wherein the sense strand is between 12 and 19 nucleotides in length.
53. The siRNA molecule of claim 52, wherein the sense strand is 15 nucleotides in length.
54. The siRNA molecule of claim 52, wherein the sense strand is 16 nucleotides in length.
55. The siRNA molecule of claim 52, wherein the sense strand is 18 nucleotides in length.
56. The siRNA molecule of any one of claims 1 to 55, wherein the length of the antisense strand is between 10 and 30 nucleotides.
57. The siRNA molecule of claim 56, wherein the length of the antisense strand is between 12 and 30 nucleotides.
58. 58. The siRNA molecule of claim 57, wherein the length of the antisense strand is between 15 and 30 nucleotides.
59. 59. The siRNA molecule of claim 58, wherein the length of the antisense strand is between 18 and 30 nucleotides.
60. The siRNA molecule of claim 59, wherein the length of the antisense strand is between 18 and 25 nucleotides.
61. The siRNA molecule of claim 60, wherein the length of the antisense strand is between 18 and 21 nucleotides.
62. The siRNA molecule of claim 61 , wherein the antisense strand is 18 nucleotides in length.
63. The siRNA molecule of claim 61 , wherein the antisense strand is 20 nucleotides in length.
64. The siRNA molecule of claim 61 , wherein the antisense strand is 21 nucleotides in length.
65. 65. The siRNA molecule of any one of claims 1 to 64, which is a branched siRNA molecule.
66. 66. The siRNA molecule of claim 65, which is biantennary, triantennary, or tetraantennary.
67. 67. The siRNA molecule of claim 66, which is a biantennary siRNA molecule, optionally represented by any one of formulas XVII to XIX: 【Chemistry 2】 wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
68. 67. The siRNA molecule of claim 66, which is a tri-antennary siRNA molecule, optionally represented by any one of formulas XX to XXIII: 【Chemistry 3】 wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
69. 67. The siRNA molecule of claim 66, which is a four-branched siRNA molecule, optionally wherein the four-branched siRNA molecule is represented by any one of formulas XXIV-XXVIII: 【Chemistry 4】 wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.
70. 70. The siRNA molecule of any one of claims 67 to 69, wherein the linker is selected from the group consisting of one or more consecutive subunits of ethylene glycol, alkyl, carbohydrate, block copolymer, peptide, RNA, and DNA.
71. The siRNA molecule of claim 70, wherein the one or more consecutive subunits are between 2 and 20 consecutive subunits.
72. A pharmaceutical composition comprising the siRNA molecule of any one of claims 1 to 71 and a pharma- ceutically acceptable excipient, carrier, or diluent.
73. 73. A method of delivering an siRNA molecule to the central nervous system (CNS) of a subject diagnosed with an epilepsy syndrome, comprising administering to said subject a therapeutically effective amount of an siRNA molecule described in any one of claims 1 to 71 or a pharmaceutical composition described in claim 72.
74. 73. A method for treating an epilepsy syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an siRNA molecule according to any one of claims 1 to 71 or a pharmaceutical composition according to claim 72.
75. 75. The method of claim 73 or 74, wherein the epilepsy syndrome is frontal lobe epilepsy, occipital lobe epilepsy, mesial temporal lobe epilepsy, parietal lobe epilepsy, benign myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, Lennox-Gastaut syndrome, West syndrome, sleep-related hyperkinetic epilepsy, progressive myoclonic epilepsy, febrile convulsions, epilepsy with persistent spike-and-wave during slow-wave sleep, Landau-Kleffner syndrome, Rasmussen syndrome, epilepsy due to inborn errors of metabolism, infantile epilepsy with migrating focal seizures, autosomal dominant nocturnal frontal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and / or multifocal epilepsy.
76. A method for reducing potassium KCNT1 expression in a subject in need thereof, comprising administering to the CNS of the subject a therapeutically effective amount of an siRNA molecule described in any one of claims 1 to 71 or a pharmaceutical composition described in claim 72.
77. 77. The method of claim 76, wherein upon administration of the siRNA molecule or pharmaceutical composition to the subject, the subject exhibits a selective reduction in KCNT1 expression over the expression of one or more other voltage-gated potassium ion channel genes.
78. The method of any one of claims 73 to 77, wherein the siRNA molecule or the pharmaceutical composition is administered to the subject by intracerebroventricular or intrathecal injection.
79. The method of any one of claims 73 to 78, wherein the subject is a human.
80. A kit comprising an siRNA molecule according to any one of claims 1 to 71, or a pharmaceutical composition according to claim 72, and a package insert, the package insert instructing a user of the kit to carry out a method according to any one of claims 73 to 79.
